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Abstract 
Systems Toxicology: mining chemical-toxicity signaling paths to enable network medicine 
Kaushal Desai 
Xiaohua Hu, Ph.D. 
 
Systems toxicology, a branch of toxicology that studies chemical effects on biological 
systems, presents exciting knowledge discovery challenges for the information researcher. The 
exponential increase in availability of genomic and proteomic data in this domain needs to be 
matched with increasingly sophisticated network analysis approaches. Improved ability to mine 
complex gene and protein interaction networks may eventually lead to discovery of drugs that 
target biological sub-networks (‘network medicine’) instead of individual proteins.  
In this thesis, we have proposed and investigated the use of a maximal edge centrality 
criterion to discover drug-toxicity signaling paths inside a human protein interaction network. 
The signaling path detection approach utilizes drug and toxicity information along with two 
novel edge weighting measures, one based on edge centrality for detected paths and another 
using differential gene expression between tissues treated with toxicity-inducing drugs and a 
control set.  Drugs known to induce non-immune Neutropenia were analyzed as a test case and 
common path proteins on discovered signaling paths were evaluated for toxicological 
significance. In addition to investigating the value of topological connectivity for identification 
of toxicity biomarkers, the gene expression-based measure led to identification of a proposed 
biomarker panel for screening new drug candidates. 
Comparative evaluation of findings from the DTSP approach with standard microarray 
analysis method showed clear improvements in various performance measures including true 
positive rate, positive predictive value, negative predictive value and overall accuracy. 
Comparison of non-immune Neutropenia signaling paths with those discovered for a control 
set showed increased transcript-level activation of discovered signaling paths for toxicity-
inducing drugs. 
xi 
 
We have demonstrated the scientific value from a systems-based approach for identifying 
toxicity-related proteins inside complex biological networks. The algorithm should be useful 
for biomarker identification for any toxicity assuming availability of relevant drug and drug-
induced toxicity information. 
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CHAPTER 1: INTRODUCTION 
 
 The problem of mining for meaningful information inside complex networks has recently 
attracted the information researcher’s attention in a wide variety of domains, including but not 
limited to the network of hyperlinks on the internet [Barnett 2005] , network of social 
interactions among human participants [Shaikh et al. 2007], diffusion of knowledge inside 
organizations [Owen-Smith and Powell 2004], literature citation networks [Chen et al. 2008] 
and molecular interactions in complex organisms [Alfarano et al. 2005]. In the life sciences 
domain, the human genome project and subsequent advances in high-throughput technology 
were expected to transform medical research through elucidation of components that formed 
the cellular machinery. However, it was soon realized that the ‘parts list’ that emerged from 
human genome sequencing was far from a ‘wiring diagram’ and ‘circuit logic’ required to 
understand complex linkages between the genotype (i.e. organism’s genetic makeup), the 
phenotype (i.e. organism’s observable traits or characteristics) and the environment 
[Quackenbush 2007]. Molecular interactions between individual parts or constituents 
including genes, proteins and metabolites need to be examined at the level of pathways, cells, 
tissue and organ to ultimately understand the physiology of the entire organism or system. The 
field of systems biology has emerged to address this gap using a holistic approach that blends 
biomedical science, computational modeling and high-throughput experimentation to provide 
an understanding of cell signaling, developmental biology, cell physiology and metabolic 
networks [Oprea et al. 2007].  
Systems biology approaches have leveraged network science for three primary goals – 
Network Inference, Network Analysis and Network modeling. Biological network inference 
refers to the problem of inferring the structure of biological networks and the state of network 
elements to construct an interaction graph underlying the system. Biological network analysis 
refers to the use of graph theory to analyze a known (complete or incomplete) interaction 
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graph and to extract new biological insights and predictions from the results. Dynamic 
biological network modeling aims to describe how known interactions among defined 
elements determine the time course of the state of the elements, and of the whole system, 
under different conditions. A dynamic model of the cellular machinery allows researchers to 
study changes in the system’s behavior due to external perturbations like drug administration 
[Albert 2007]. Systems and Network biology are therefore important in terms of their 
potential applications to drug discovery and development. 
 A steady increase in the number of drug candidates failing in late-stage clinical 
development over the past decade has been concurrent with the assumption of a ‘one gene, 
one drug, one disease’ paradigm [Hopkins 2008]. Also, recent evidence has challenged the 
paradigm of single target intervention in drug discovery and development. Studies have 
shown that phenotypes are robust to single gene-knockout and only about 19% genes are 
essential across a number of model organisms. It is therefore, conceivable that the robustness 
of phenotype can be understood in terms of redundant function and alternative compensatory 
signaling routes inside complex biological networks [Hopkins 2007]. Polypharmacology, 
defined as the specific binding of a drug to multiple targets, and its effect on biological 
networks and phenotypes is therefore important to understand in the context of the need to 
evaluate drug safety as well as drug efficacy.   
1.1 Drug-induced toxicity evaluation: need for In silico approaches 
 The ability to understand and reliably  predict adverse effects of drug administration on 
biological systems before the drug is administered in humans continues to be a major 
challenge for pharmaceutical research and development. WHO defines an adverse drug 
reaction as ”a response to a drug that is noxious and unintended and occurs at doses normally 
used in man for the prophylaxis, diagnosis or therapy of disease, or modification of 
physiological function” [Edwards and Aronson 2000]. Definition and examples of different 
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types of adverse drug reactions is outlined in Table 1. In the context of this thesis, it is 
important to note the difference between Type A (Dose-related) and Type B (Non-dose 
related) adverse drug reactions. While Type A drug reactions are directly related to the 
pharmacological action of the drug, Type B reactions include immunological or 
hypersensitivity type reactions, that are not related to the pharmacological action of the drug.  
TABLE 1. Types of Adverse Drug Reactions with examples 
 
 The use of computational methods for evaluation of toxic potential for new chemical 
entities is termed as In silico toxicity evaluation. A variety of in vivo (inside a living 
organism, e.g. animal studies) and in vitro (outside a living organism, e.g. test tube or assay-
based evaluation) toxicity screens are available for screening drug candidates. More recently, 
high-throughput technologies have provided the ability to measure changes in mRNA 
(messenger RNA) levels for thousands of gene transcripts on a single chip. This, combined 
with advances in proteomics (ability to measure proteins as products of translation using 
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protein expression, MS and other protein-based measurement technologies) has led to an 
explosion in gene and protein-level information inside publicly available databases. While 
current approaches for analyzing genomic and proteomic data have been successful to some 
extent, it is expected that a ‘systems’ level approach that integrates these diverse data types 
will provide insights that are likely to improve the success of the drug development process 
[Ganter et al. 2006]. It is expected that viewing drug action through the lens of network 
biology may provide insights into the safety and efficacy of novel pharmaceutical agents.  
 The high-level objective of this dissertation is to improve In silico toxicity evaluation 
using network biology.  
1.2 Characteristics of Biological Networks 
A network can be defined as a graphical structure with nodes as their fundamental units. 
The interconnections between nodes in a network are represented by weighted or unweighted 
edges. Each node may represent a physical or conceptual entity from the specific domain of 
study. In case of complex biomolecular networks, the nodes may represent genes, proteins or 
other cellular components connected by edges that represent interactions between cellular 
components including chemical reactions and biophysical interactions. A network model of 
biological entities is used to represent complex interactions that result in biological changes as 
a result of environmental stimulus at the cellular, tissues/organ and organism level. 
In order to understand the characteristics of real world networks, many theoretical network 
models have been proposed. Network models and their parameters provide an overview of the 
global structure or topology of these important cellular networks. The most general level of 
network analysis comes from global network measures that allow us to characterize and 
compare the given network topologies (i.e. the configuration of the nodes and their connecting 
edges). Global measures such as the degree distribution (the degree of a node is the number of 
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edges it participates in) and the clustering coefficient (defined in section 2.1) have recently 
been thoroughly reviewed in the context of cellular networks and in proteomics.  
The small-world model is defined as one where any two nodes in the network can be 
connected through a much shorter path than would be expected in a random network of 
similar size and number of connections. Metabolic networks have been found to be small-
world networks and additionally, the network diameter does not appear to vary between 
different organisms [Alm and Arkin 2003]. Small-world networks have low average path 
lengths and high clustering coefficients.  
Scale-free networks are characterized by a connectivity distribution that decays as power 
law.   
P(k) = Ak
-γ
 
 where A is the normalization constant and the degree exponent γ is between 2 and 3 
[Albert 2007, Barabasi and L. 1999, Jeong et al. 2000]. Essentially, this means that there are a 
small but finite number of highly connected nodes in the system, forming the so-called ‘hubs’. 
It has been shown that many biological networks follow a power-law distribution, including 
protein families, super-families, folds, short DNA words and even pseudogene families 
[Luscombe et al. 2002]. Like small-world networks, scale-free networks have low average 
path lengths and high clustering coefficients. 
 The non-random nature of biological networks has to do with the biological functions of 
nodes and edges. Several studies in yeast have revealed correlations between the topology and 
composition of a network and important biological properties of nodes [Jeong et al. 2001]. 
The well-connected hubs are largely represented by evolutionary conserved proteins because 
the interactions impose certain structural constraints on sequence evolution [Fraser et al. 
2002].  
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 It is important to study biological phenomena at a systems level because certain properties 
of biological networks can only be observed at that level. Table 2 defines  properties like 
modularity, robustness, redundancy etc. with a biological example from the process of 
hemostasis and coagulation. 
 Recently, another topological feature of the network has received attention – betweenness, 
which measures the total number of non-redundant shortest paths going through a certain node 
or edge. Betweenness was originally introduced to measure the centrality of the nodes in the 
network [Yu et al. 2007]. Girvan and Newman proposed a network partitioning algorithm, 
based on the shortest-path algorithm in graph theory, that iteratively removes edges with the 
highest betweenness until the network breaks down into individual clusters [Girvan and 
Newman 2002]. Multiple authors have proposed improvements over the Garvin and Newman 
approach, including the use of ‘edge clustering coefficient’ [Radicchi et al. 2004], combining 
clique detection, superparamagnetic (SPC) clustering and Monte Carlo optimization (MC) to 
search for functional modules in yeast protein network [Spirin and Mirny 2003].  Chapter 3 
describes the implementation of an edge betweenness centrality measure to discover signaling 
paths associated with drug-induced toxicity.  
 While large-scale characteristics of biological networks (e.g. small-world, scale-free) 
provide insight into topological properties at a network-wide level, it has been observed that 
the most important biological processes such as signal transduction, cell-fate regulation, 
transcription and translation involve more than four but much fewer than hundreds of proteins 
[Spirin and Mirny 2003]. It is believed that most relevant processes in biological networks 
correspond to the meso scale (5-25 genes/proteins). Algorithms for identification of clusters 
(sets of proteins having many more interactions among themselves than with the rest of the 
network) have led to discovery of protein complexes and functional modules inside interaction 
networks. 
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TABLE 2. Properties of Biological networks 
 
 
Functional modules consist of proteins that participate in particular cellular processes while 
binding to each other under specific conditions (e.g. after drug administration, during specific 
cell cycle phases, inside specific cellular compartments etc.).  Protein/Module function 
prediction under drug administration conditions may help reveal the mechanism of action for 
the drug and identification of its toxic effects early during drug development.  
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1.3   Research Objectives 
This thesis focuses on the following research questions – 
1) Can the use of a network model provide insights into mechanisms of drug-
induced toxicity? 
2) How can toxicity related proteins or ‘hot spots’ be discovered inside biological 
networks? 
3) What is the biological significance of discovered ‘hotspots’ with respect to the 
drug-induced toxicity being evaluated? 
Evaluation of a candidate drug for potential toxicities during early stages of drug research is 
challenging due to absence of experimental evidence in humans. Animal studies don’t always 
provide an accurate estimate of probability of occurrence for a particular effect in humans and 
also cannot represent human cellular interactions completely. The use of animal testing also 
needs to be minimized for ethical reasons. The emergence of novel high-throughput 
technologies has therefore, led to emphasis on ‘In silico’ (computational) approaches to 
toxicity evaluation.  Use of biological networks for drug-induced toxicity evaluation has been 
challenging for various reasons. First, the scientific information required to construct various 
elements of such a network (genes, proteins, phenotypes etc.) is dispersed across multiple 
public databases and inside an ever-growing volume of published literature [Dietmann et al. 
2006]. Use of standardized vocabularies and taxonomies for various biological annotations 
has recently enabled genome-wide, cross-platform integration of biomolecular data into 
system-wide biological networks. Second, analysis of the integrated biological network 
requires computationally intensive mining algorithms that can handle very large networks. 
The exponential increase in availability of genomic and proteomic data in this domain needs 
to be matched with increasingly sophisticated network analysis approaches. As an example, 
Steffen et al. discovered MAPK signaling paths inside a filtered yeast protein-protein 
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interaction (PPI) network consisting of 5560 interactions and 3725 proteins [Steffen et 
al. 2002]. Compared to this, the human subset of STITCH database (version 1.0) 
consists of ~18600 proteins and ~1432500 unique protein-protein interactions. Mining 
such a large network to elucidate toxicity-related proteins, requires sophisticated 
algorithmic approaches that can run in reasonable time with manageable 
computational burden. Third, the identified protein or set of proteins should have 
toxicological relevance to the effect being evaluated. Analysis of networks may yield insights 
into a wide variety of physiological processes. However, it is important to be able to 
distinguish between a physiological effect that is ’normal’ from effects that can be directly 
associated with external stimuli like drug administration. Similarly, external stimuli can 
typically lead to a wide variety of clinical effects. It is therefore important for network 
algorithms to be able to associate a particular systemic change to a specific clinical 
manifestation, namely drug-induced toxicity.  
If the above challenges can be addressed appropriately, a network-based model may 
capture the complexity of human physiological networks more accurately compared to 
toxicity screens that are based on studying the effects of drug administration on one or a few 
proteins and their interactions. Dynamic programming and fixed parameter tractability offers 
solutions to problems that not very long ago, were considered computationally intractable. The 
challenge for an information researcher is to utilize domain knowledge and develop algorithms 
that can leverage advances in applied mathematics to discover knowledge inside complex 
networks.  The primary motivation for this thesis is to devise analytical methodologies that 
can mine such large biological networks to provide insights into drug effects. This thesis 
proposes and implements two algorithms that leverage multiple sources of information and 
mine a biological network for protein modules or ’hot spots’ that may be associated with a 
particular drug-induced toxicity. The algorithms are then compared with findings from 
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microarray data analysis, the prevalent approach for identification of biomarkers of drug-
induced toxicity. Finally, thesis contributions and directions for future work are summarized 
in chapter 6. 
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CHAPTER 2: BACKGROUND AND RELEVANT WORK 
 
Many drug candidates fail in clinical trials and are withdrawn because of unforeseen 
effects of human metabolism, such as toxicity and unfavorable pharmacokinetic profiles. 
Early pre-clinical elimination of such compounds is important but not always possible, due to 
lack of accurate and reliable predictive models. Three broadly defined resources have been 
considered as components of pharmaceutical In silico toxicity evaluation systems [Bugrim et 
al. 2004] –  
First, chemical structure-activity relationships (SAR) computational models are built 
within groups of structurally similar compounds and aimed at effective prediction based on 
experimental data (toxicity end points, metabolic products and intermediates). The SAR 
approach leverages empirical rules for modeling metabolism and toxicity based on chemical 
structure of lead compounds. 
 The second set of technologies relevant to an In silico toxicity evaluation system is 
collectively referred to as ‘toxicogenomics’ platforms. Toxicogenomics has been defined as 
an integration of genomics and toxicology [Gomase and Tagore 2008]. It is a branch of 
science that aims to study the interaction between the cell’s genome, chemicals in the 
environment and disease.  Toxicogenomics studies classify toxicities based on gene 
transcriptional patterns observed on high-throughput gene expression platforms using tissues 
relevant to specific toxicological endpoints. Patterns from new chemicals and tissue samples 
can be compared with those in ‘reference’ databases to extrapolate the probability of toxicity 
[Bugrim et al. 2004]. 
 The third source of information relevant to In silico toxicity prediction is function 
pathway databases and enzymatic reaction repositories. These systems biology databases 
capture information around chemical reactions, metabolic cascades and signal transduction 
routes across a variety of transporters, metabolizing enzymes and protein interaction. 
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 Advances in structure-activity computational models and ‘omics’ approaches to toxicity 
evaluation are relevant to this work and will therefore be discussed in section 2.1. 
Individually, none of these technologies is sufficient for the task of predicting the ADME 
(Absorption, Distribution, Metabolism and Excretion)/ Tox (toxicity) behavior of new 
chemical entities [Bugrim et al. 2004]. For example, empirical structure-based models do not 
deal with the underlying mechanisms of toxicity and metabolism, genomics-based systems 
and patterns resulting from analysis of data on a single platform have limited value in the 
absence of validation from other experimental and observational sources and pathway 
databases do not reflect the spatial or temporal patterns of pathway activity, and therefore 
reflect the functional potential of a cell or tissue rather than the real activity in response to 
stimuli. Because the understanding of metabolism and toxicity is a systems-level problem, the 
solution requires integration of data from various sources into one comprehensive model. 
Section 2.2 and 2.3 review two areas that address the need for a ‘systems’ level approach, 
namely network biology which aims to analyze complex networks created through integration 
of multiple sources of biomolecular data and automated signaling path detection, a set of 
algorithms aimed at automated discovery of signaling paths inside large biomolecular 
networks. 
2.1 In silico Toxicity Evaluation Methods: Recent advances  
2.1.1 Advances in structure-activity (SAR) based ADME/Tox modeling 
In silico ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) 
modeling has received increasing attention in the post-genomic era. From some of the early 
reviews of systems biology it has been proposed as an approach to understanding 
pharmacodynamic and toxicological properties of chemical entities [Kitano 2002, Ekins 2006].   
 Expert systems based approaches have aimed to go beyond the limitations of traditional 
quantitative structure-activity relationship (QSAR) models for prediction of drug activity. 
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Expert systems fall into four broad categories – automated QSAR, knowledge-based systems, 
automated rule derivation and decision tree-based algorithms [Dearden 2003]. More recent 
advances in ADMET modeling are exemplified by software systems like TOPKAT
TM
, 
CASE
TM
, DEREK
TM
, HazardExpert
TM
 etc. Both TOPKAT
TM
 and CASE
TM
 are automated 
QSAR expert systems where toxicity prediction is based on use of predictive models (e.g. 
linear regression for continuous toxicity endpoints like LD50 and logistic regression for 
discreet endpoints like mutagenicity and carcinogenicity). While TOPKAT uses mainly 
topological, sub-structural and electronic descriptors in its predictive model, CASE creates its 
own structural alerts by breaking down each molecule into possible fragments from two to ten 
heavy atoms. DEREK
TM
, HazardExpert
TM
 and OncoLogic
TM
 are knowledge-based expert 
systems that relie on an expert-curated rulebase for prediction of toxicity-related endpoints. 
Various endpoints including carcinogenicity, mutagenicity, teratogenicity, irritation, ACD 
(allergic contact dermatitis), acute toxicity, CYP450 2D inhibition and cellular toxicity can be 
predicted with varying degrees of accuracy using models provided by various in silico 
ADMET platforms. 
Another interesting approach related to prediction of drug effects in new chemical 
entities was termed as ‘biological spectra similarity’ by Fliri et al [Fliri et al. 2007]. The 
authors estimated similarity between 1064 drugs based on six descriptor sets starting with two 
‘signal input’ (compound structure) descriptors, two intermediate cellular level (protein-ligand 
displacement and Medline based protein-drug co-investigation) descriptors and two organism 
level (MedDRA-based literature mining and COSTART based literature mining for adverse 
events) descriptors as clinical manifestations of drug effects. Drug-protein association 
similarity and protein-adverse events association similarity were computed using hierarchical 
clustering to elucidate compounds with similar structure and effect relationships. For a new 
set of compounds, the authors found that compounds with high similarity based on ‘structure 
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information spectra’ also showed high similarity along the ‘effects information spectra’. The 
authors concluded that structure-effect correlations become quantifiable only within certain 
structural boundaries and that the ability to compare broad drug effects on cellular function 
with broad drug effects on organisms is a key to the design of medicines. Paolini et al. 
constructed a polypharmacology interaction network using structure-activity relationships 
(SAR) integrated from diverse sources [Paolini et al. 2006]. A global mapping of chemical 
structure, protein sequence and disease indication enabled construction of a ligand-target 
matrix that could be used as a probabilistic model to predict pharmacology from a large 
knowledgebase. The authors could predict potential activity of a compound against the protein 
space with 56.7% accuracy, representing a 153-fold enrichment over random.  
 A major limitation of QSAR-based approaches is the scarcity of experimental data outside 
a small chemical space of well-studied chemical structures and endpoints like carcinogenicity, 
mutagenicity etc. In order for a QSAR to model biological data well and to be predictive, all 
the compounds involved should act by the same mechanism, since the physico-chemical and 
structural descriptors used in the QSAR are deemed to reflect mechanism of action [Dearden 
2003]. Moreover, expert systems are aimed at prediction of toxicity elucidation and don’t 
directly contribute to elucidation of molecular mechanisms of toxicity. High-throughput 
technologies like genomics and proteomics may help address this limitation. 
2.1.2  Advances in ‘Omics’ approaches to In silico toxicity evaluation 
 ’Omics’ approaches consist of genomics, proteomics and metabonomics for evaluation of 
drug-induced toxicity. High-throughput genomics data is abundantly available from gene 
expression or microarray platforms while proteomics data is also more recently being made 
available in the public domain in the form of protein binding/interaction and protein 
expression data. 
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 Waring et al. investigated whether gene expression profiles can be used for In silico 
toxicity evaluation, by profiling gene expression in rats treated with 15 different known 
hepatotoxins [Waring et al. 2001]. Results showed a strong correlation between the 
histopathology, clinical chemistry and gene expression profiles induced by these agents, 
thereby confirming that gene expression data may provide insights into drug-induced toxicity 
similar to other well-established methods.  
 Lamb et al. proposed gene expression signature similarity as a means to connect diseases, 
genetic perturbation and drug action [Lamb et al. 2006]. The authors constructed a 
‘Connectivity map’ using gene expression profiles for 164 distinct small molecule 
perturbagens inside four different types of cell lines, 6 hours and 12 hours after compound 
treatment. Using a non-parametric, rank-based pattern matching strategy, the authors were 
able to identify compounds from the same class (HDAC inhibitors) using a class-specific 
query signature, as shown in Figure 1. The connectivity map identified compounds with 
negative connectivity as well as compounds with similar effects. Most of the signatures were 
generated from a single cell type. Signatures linked diseases to genes and genes to drug effects 
only on the basis of gene expression changes, without necessarily arriving at a toxicity-related 
functional module and without use of proteomic information that confirms the post-
translational changes that may validate gene expression-based observations. 
The task of predicting the extent to which various proteins play a role in drug-induced toxicity 
may be considered analogous in its intent to the task of assigning new functional association to 
proteins with unknown function. In this context, approaches collectively referred to as ‘guilt by 
association’ are relevant to this work. Guilt by association has been broadly defined as the use 
of contextual information for in silico inference of protein function [Aravind 2000].  Various 
types of contextual information have previously been used in order to predict protein function, 
including phyletic profile (pattern of occurrence of orthologs of a particular gene in a set of 
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genomes under comparison), sequence homology and gene neighborhood along the 
chromosome [Huynen et al. 2000]. More recent approaches that integrate genomic and 
proteomic information and utilize biological networks may also be broadly categorized as ‘guilt 
by association’ [Dittrich et al. 2008].  
Figure 1.  The connectivity map concept, reproduced from Lamb et al. [Lamb 2007]. a.  
Gene expression profiles derived from the treatment of cultured human cells with a large 
number of perturbagens populate a reference database. Perturbagens are ranked by a 
connectivity score that represents the direction and strength of enrichment of a query signature 
with each reference profile. b.  PPARγ agonists are connected with diet-induced obesity in 
Rats. 
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 However, algorithms that can mine large biological networks to elucidate the role of 
specific proteins in drug-induced toxicity are yet to be developed. The next section reviews 
network-based approaches in detail. 
2.2 Advances in Network Biology 
 Two areas of application for network biology are relevant to this thesis – first, algorithms 
that predict protein function based on their topological and other characteristics inside 
biological networks are relevant because as mentioned in the research objectives, one of the 
primary goals of this thesis is to discover toxicity-related proteins inside a large biological 
network. Second, approaches that analyze disease-gene-drug networks are important because 
one of the goals of this thesis is to discover relationships between genes/proteins and drug-
related effects that manifest as adverse events after drug administration. Section 2.2.1 and 
2.2.2 review these two research areas in network biology. 
2.2.1 Network-based prediction of protein function 
 Current approaches to prediction of protein function have relied on network topology 
(connectivity of unannotated and annotated proteins in the network) as well as their known 
functional association [Sharan et al. 2007, Chua et al. 2006, Letovsky and Kasif 2003, Hu et 
al. 2007].  
 Sharan et al. distinguished between two types of approaches, namely Direct annotation 
schemes , which infer the function of a protein based on its connections in the network and 
Module-assisted schemes , which first identify modules of related proteins using different 
approaches and then annotate each module protein based on known function of its members, 
as shown in Fig. 2. 
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Figure 2.  Direct versus module-assisted approaches for functional annotation (reproduced 
from Sharan et al. 2008 [Sharan et al. 2007]). The scheme shows a network in which some 
proteins have known annotations. Proteins with the same function are shown to have the same 
color. Unannotated proteins are in white. The direction of edges indicates influence of 
annotated proteins on unannotated ones. 
 
 Direct Annotation approaches include simple neighborhood counting, where the function 
of a protein is determined by known function of its immediate neighbors. The basic 
neighborhood counting methods don’t provide a statistical significance level or a level of 
confidence for predicted functional annotations [Schwikowski et al. 2000]. Hishigaki et al. 
proposed a variation to the simple neighborhood counting by computing a γ2-like score for 
function assignment for all n-neighboring proteins [Hishigaki et al. 2001]. Within the n-
neighborhood, proteins at different distances from p are treated in the same way. Chua et al 
tried to tackle the problem by investigating the relation between network distance and 
functional similarity [Chua et al. 2006]. Considering just the 1- and 2-neighborhoods of a 
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protein, a functional similarity score was computed to assign different weights to proteins 
according to their distances from the target protein. 
 Graph theoretic methods take into account the full topology of the network and mainly 
consist of two types of approaches - cut-based and flow-based. Vazquez et al. aimed at 
assigning a function to each unannotated protein so as to maximize the number of edges 
between proteins with the same function [Vazquez et al. 2003]. The authors computed a score 
that counted the number of interacting proteins with the same functional assignment and 
associated it with any given configuration of functions for the whole set of unannotated 
proteins. The objective of the algorithm was to minimize the score so as to find a 
configuration with the least number of interactions between proteins not annotated with the 
same function. Function prediction therefore became a global optimization problem where 
multiple solutions were possible. The authors therefore, developed an ’objective’ way to 
assing multiple functions to some proteins, depending on whether multiple solutions were 
available to achieve the minimum score configuration. Karaoz et al. applied a similar 
approach but considered one function at a time and compared two types of edge weighting 
approaches, one that captured only qualitative functional links between proteins and one that 
integrated gene co-expression so that the weight of an edge in the integrated network was the 
absolute value of the correlation coefficient of the gene-expression profiles of the pair of 
interacting proteins [Karaoz et al. 2004]. Deng et al. applied a Markov Random Fields 
approach to assign function to unannotated proteins based on function of annotated proteins 
and presence of interaction between proteins with known function [Deng et al. 2003].  
 Module-assisted methods differ in their approach for detecting functional modules inside 
the network. Some module detection algorithms are solely based on network topology while 
others utilize additional data sources, such as gene expression measurements or deletion 
phenotypes. Bader et al. used a core clustering coefficient to add interaction weights to edges 
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in the network and applied a greedy search algorithm to discover modules [Bader 2003]. In 
order to predict the size of a cluster or module, the authors developed a mathematical model 
for the expected number of closed loops in a clustered network. Comparing observations on 
the actual network with those from randomized networks, the analytical model predicted a 
cluster size of 15 ± 2 proteins. Hierarchical clustering approaches have also been used with a 
variety of similarity measures for module identification. It has been shown that pairwise 
distances may not be appropriate as a similarity measure because they tend to be identical 
between many protein pairs [Arnau et al. 2005]. King et al. partitioned the nodes of a given 
graph into distinct clusters, depending on their neighboring interactions, with a cost-based 
local search algorithm that updates a list of already explored clusters that are forbidden in later 
iteration steps. Clusters with either low functional homogeneity, cluster size or edge density 
were filtered out [King et al. 2004]. It has been postulated that module members may have 
similar shortest-path profiles. This criteria has been applied to identify modules inside small 
subnetworks, along with other properties like centrality measures [Dunn et al. 2005]. Several 
methods use expansion of complex seeds to find protein complexes. The SEEDY algorithm 
constructs complexes by adding proteins to a given seed, as long as the reliability of the most 
reliable path from a candidate to the seed does not fall below a certain threshold [Bader 2003]. 
Wu and Hu proposed an algorithm called Commbuilder that accepts a seed protein, gets the 
neighbors (FindCore component), finds the core of the community to build and expands the 
core (ExpandCore component) to find the eventual community [Hu and Wu 2007]. Findcore 
performs a naive search for maximum clique from the neighborhood of the seed protein by 
recursively removing vertices with the lowest in-community degree until all vertices in the 
core set have the same in-community degree. ExpandCore performs a breadth-first expansion 
to first create a set containing the core and all neighbors of the core. It then adds to the core a 
vertex that either meets the quantitative definition of a community in a strong sense (i.e. 
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number of edges connecting the vertex to vertices within the core is greater than the number 
of edges connecting the vertex to vertices outside the core) or the fraction of in-community 
degree over a relaxed (user-defined) affinity threshold of the size of the core. The affinity 
threshold is 1 when the candidate vertex connects to each of the vertices in the core set.   
 While the above approaches are useful for predicting protein functional association, 
identification of proteins that may play a role in drug-induced toxicity requires incorporation 
of background knowledge about the drug and the toxicity under consideration. Drug 
administration perturbs the biological network at specific ‘nodes’ (referred to as drug target 
proteins) that may be several levels upstream (or several nodes apart in terms of distance) 
from toxicity-related ‘end nodes’ in the network. Mapping the cascade of proteins associated 
with drug response and identification of network ‘hotspots’ is therefore, a central challenge in 
toxicity evaluation.  
2.2.2 Analysis of Disease-Gene-Drug Networks 
Network biology has recently been used to mine gene-protein-disease-drug networks 
[Yildirim et al. 2007, Goh et al. 2007, Xu and Li 2006, Ekins et al. 2005]. Yildrim et al. 
constructed a bipartite network of all FDA approved drugs and their protein targets using data 
from the drugbank database [Yildirim et al. 2007]. The resulting network was analyzed to 
elucidate an overabundance of ‘follow on’ drugs (drugs that ‘hit’ previously known targets) 
and a trend towards greater polypharmacology through functionally diverse targets for 
emerging drugs.  The authors also found significant differences between ‘palliative’ and 
‘etiological’ drugs with respect to the shortest distance between the drug targets and their 
respective gene products.  
 Goh et al. constructed a human disease network using gene-disease associations found in 
the NCBI- OMIM (Online Mendelian Inheritance in Man) database [Goh et al. 2007]. Genes 
associated with similar disorders showed higher likelihood of physical interactions between 
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their products and higher expression profiling similarity of their transcripts, supporting the 
existence of distinct disease-specific functional modules. While essential human genes were 
found to be more likely to encode ‘hub’ proteins and were expressed more widely in most 
tissues, majority of the non-essential genes were located on the periphery of the human 
disease network.  
 Identification of functional modules [Chen, et al. 2006], ‘hubs’ or ‘hot spots’ [Begley, et 
al. 2004,] in protein-protein interaction networks is considered the first step towards 
understanding the organization and dynamics of cell function [Hu and Wu 2007]. In silico 
toxicity evaluation and prediction approaches are yet to benefit from insights gained from a 
systematic analysis of biological networks.  
2.3 Discovering signaling paths in biological networks 
 With the advent of genomic and proteomic data, various approaches have been proposed 
to discover biologically meaningful substructures such as dense groups of interacting proteins 
and loop structures. Linear pathways play an important role in signal transduction inside 
biological networks. They are easy to understand and analyze and, as demonstrated by Ideker 
et al. for galactose metabolism in Yeast, they can serve as seed structure for experimental 
investigation of more complex mechanisms [Ideker et al. 2001, Hüffner et al. 2008].  
Steffen et al. constructed a network of 5560 non-redundant protein-protein interactions 
among more than 3725 proteins using yeast-two-hybrid technique and ran an exhaustive search 
to identify all possible linear paths up to length eight starting at any membrane protein and 
ending at transcription factors. The search was applied to an unweighted interaction graph, 
considering all interactions equally reliable. Microarray data was then used to rank all paths 
according to the degree of similarity in the expression profiles of pathway proteins. The 
algorithm, called NetSearch, was able to reproduce many of the essential elements of known 
MAPK pathways in Yeast [Steffen et al. 2002]. Kelly et al., developed an efficient algorithm 
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(called PATHBLAST) to detect simple paths in a graph that is based on finding acyclic 
orientations in the graph’s edges [Kelley et al. 2003]. More recently, network algorithms for 
detecting signaling paths have improved upon earlier approaches in two ways –  
a. Assignment of reliability score to interactions (use of weighted graph) and  
b. Use of a powerful algorithmic technique by Alon et al. [Alon et al. 1995] called color 
coding, to find high-scoring paths efficiently.  
A more efficient algorithm like color coding is necessary for detection of signaling paths 
because the problem of finding linear pathways in a large network is NP Hard or 
computationally intractable (the travelling salesman problem is reducible to it). NP-Hardness 
implies an inherent combinatorial explosion in the solution space that leads to running times 
growing exponentially with the input size. This means that large instances of NP-hard problems 
cannot always be solved efficiently to optimality. Heuristics drop the demand for useful 
running time guarantees and are tuned to run fast with good results on typical instances. 
Approximation algorithms trade the demand for optimality for a provably efficient running 
time behavior, while still providing provable bounds on the solution quality. However, these 
methods have serious drawbacks. In many applications, it is not acceptable that there is a 
chance that the algorithm might take exceptionally long in corner cases; and the approximation 
guarantees that are typically obtained are rather weak and it has been shown that a guarantee 
such as 10% error is often not attainable [Hüffner 2007]. Parameterized complexity, as 
accomplished with the color coding approach, offers a third alternative where the structural 
complexity is measured with a nonnegative parameter (denoted by k) such that growth of the 
running time is determined by both, the input size and the parameter k . Algorithms that 
leverage parameterized complexity, confine the combinatorial explosion to the parameter such 
that instances solve fast whenever the parameter is small. As explained by Hüffner et al. 
[Hüffner 2007], Fixed Parameter Tractability (FTP) is different from ‘polynomial time solvable 
24 
 
for fixed k’; an algorithm running in O(nk) time demonstrates that a problem is polynomial-time 
solvable for any fixed k , but does not show fixed-parameter tractability. 
 Color coding is a randomized algorithm for finding simple paths and simple cycles of a 
specified length k  within a given graph. Consider a weighted interaction graph in which each 
vertex is a protein and each edge (u, v) represents an experimentally observed interaction 
between proteins u and v, and is assigned a numerical value p(u, v) representing the 
probability that u and v interact. Each simple path in this graph can be assigned a score equal 
to the product of the values assigned to its edges. Among paths of a given length, those with 
the highest scores are plausible candidates for being identified as linear signal transduction 
pathways. Scott et al. extended the color coding algorithm to accurately recover well-known 
MAP Kinase and ubiquitin-ligation pathways [Scott et al. 2006]. The implementation 
however, was limited to path lengths of 10 vertices and moreover, required some hours of run 
time. Hüffner et al. used a dynamic programming approach to enable detection of paths up to 
a length of 20 vertices in some hours. The task of finding pathways of length 10 could be 
accomplished in a few seconds [Hüffner et al. 2008].  
 Following Hüffner et al., an implementation of the color coding algorithm can be 
summarized as follows: 
 The network is modeled as an undirected graph where each protein is a vertex and each 
edge is weighted by the negative logarithm of the interaction probability for the two proteins it 
connects. In other words, in order to work with an additive weight rather than a multiplicative 
one and to formalize the problem of high probability pathway candidate detection to a NP-
hard problem called MINIMUM-WEIGHT PATH, each edge is assigned a weight w(v,u) = -
logp(u,v). The weight of a path is defined as the sum of the weights of the edges and the 
length of the path as the number of vertices it contains. 
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Algorithm: COLORCODING(G = (V,E)) 
1 repeat a sufficient number of times: 
2 for each  v Є V: 
3     color v randomly; 
4 if TRIAL(G): 
5      return true 
6 return false 
Figure 3.  Algorithm pseudocode for color-coding 
 
MINIMUM-WEIGHT PATH 
Input: An undirected edge-weighted graph G = (V, E) with n:=|V| and m:=|E| and an integer k . 
Task: Find a length-k  path in G that minimizes the sum over its edge weights. 
 The primary goal with color coding is to randomly color the vertices of an input graph 
with k  colors and then search for colorful paths, that is, paths where no color occurs twice. 
Given a fixed coloring of vertices, Hüffner et al. find the minimum-weight colorful path using 
dynamic programming: Assume that for some i < k  a value W(v, S) is computed for every 
vertex v Є V and cardinality-i subset S of vertex colors; this value denotes the minimum 
weight of a path that uses every color in S exactly once and ends in v. Clearly, this path is 
simple because no color is used more than once. This value can now be used to compute the 
values W(v, S) for all cardinality -(i + 1) subsets S and vertices v Є V because a colorful 
length-(i+1) path that ends in a vertex v Є V can be composed of a colorful length-i path that 
does not use the color of v and ends in a neighbor of v. Mathematically, 
W(v, S) =  min    (W(u, S \ {color(v)}) + w(e))  
                                  e={u,v}ЄE 
 The coloring of input graph is random and hence many coloring trials have to be 
performed to ensure that the minimum-weight path is found with a high probability. One of 
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the strengths of the color coding approach is that it can be adapted to many practically 
relevant variations in problem formulation, including the problem of finding paths with 
maximum product of edge weights as an optimization criterion. As mentioned by Sharan et 
al., automated signaling path detection approaches have not been applied towards prediction 
of protein function [Sharan et al. 2007]. Chapter 3 and 4 demonstrate how the use of color 
coding technique in combination with appropriate edge-weighting criteria can be used to 
understand the role of network proteins in drug-induced toxicity. 
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CHAPTER 3: A NOVEL SYSTEMS BIOLOGY APPROACH FOR 
DETECTING TOXICITY-RELATED HOTSPOTS 
 
 This chapter describes the implementation of a novel systems biology approach for 
detecting toxicity-related proteins or sets of proteins inside a biological network. The 
algorithm, called ’Drug Toxicity Signaling Path’ (DTSP) detection, utilizes an edge centrality 
measure in conjunction with the color coding algorithm to identify toxicity-specific modules 
inside protein interaction networks.  Section 3.1 provides a conceptual description of the 
algorithm, followed by implementation details in section 3.2 and a discussion of results and 
conclusions in section 3.3 and 3.5 respectively.  
The rationale for use of protein interaction data to implement the algorithm can be 
summarized as follows – 
At least three different types of molecular interaction networks have previously been 
considered for network biology research: the protein-protein interaction network, the 
transcription regulatory network and the small-molecule metabolism network. Technologies 
like Mass Spectrometry have led to unprecedented generation of protein-protein interaction 
data at the cost of a large fraction of false-positives as well as false-negatives [Alm and Arkin 
2003]. Proteins are important players in executing the genetic program and also act as targets 
for modulating biological processes and pathways after drug administration. When carrying out 
a particular biological function or serving as molecular building blocks for a particular cellular 
structure, proteins rarely act individually. Understanding the network of proteins is important 
because drug-induced toxicity is a result of interactions between proteins, with DNA, RNA and 
small molecules that form molecular machines. These machines are modular, involve both 
static and dynamic assemblies of macromolecules, and transmit as well as respond to intra- and 
extracellular signals [Ideker and Sharan 2008]. This thesis, therefore, proposes a novel 
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analytical methodology to mine protein-protein interaction networks and discover toxicity-
related hotspots.  
3.1 Drug Toxicity Signaling Path (DTSP) Detection Algorithm 
 Beneficial, deleterious or neutral functional effects of drugs can be mediated via binding to 
the desired therapeutic target and/or to other molecular targets such as G-protein-coupled 
receptors (GPCR), ion channels, or transporters on the cell membrane, or to intracellular targets 
such as enzymes and nuclear hormone receptors [Valentin and Hammond 2008]. The effects of 
an external stimulus are propagated through a complex biomolecular network of protein-
protein interactions, starting at the drug target protein and ending in proteins associated with 
specific effects of the drug. In order to understand the molecular mechanism of toxicity and to 
identify toxicity-specific functional modules, network analysis algorithms should be able distill 
the set of proteins involved in signaling paths that link the drug target proteins to toxicity-
related proteins in the PPI network. In this thesis, such paths are defined as drug toxicity 
signaling paths (hereinafter “DTSP”). 
 Figure 4 shows a schematic representation of DTSPs for a drug and a toxicity of interest.  
A DTSP is any linear path that links one of the drug’s target proteins to a toxicity-associated 
protein within the PPI network. For a summary of graph-theoretic definitions used in this 
thesis, refer to Appendix A. 
Mathematically, a DTSP can be defined as follows – 
Let DT = { 0, 1, 2,……. k} be the set of drug target proteins in the protein interaction 
network. Let Tp = { 0, 1, 2,……. k} be the set of toxicity-related proteins in the protein 
interaction network. A Drug-Toxicity Signaling path is a term used to refer to any path that 
starts at an element of set DT and ends at an element of set Tp.  
 DTSP = { 0, 1, 2,……. k}  where 0 Є DT and k Є Tp.   
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Figure 4.  Network model schematic for drug-toxicity signaling paths 
As described in section 2.3, automated signaling path detection algorithms and variations 
thereof have recently been proposed and evaluated for Yeast biomolecular networks [Hüffner 
et al. 2008, Noga et al. 1995]. Our algorithm extends the algorithm proposed by Steffen et 
al.[Steffen et al. 2002] to make it amenable to discovery of toxicity-specific proteins inside 
large protein interaction networks and utilizes the color coding algorithm proposed by Alon et 
al.[Alon et al. 1995]. Hüffner [Hüffner et al. 2008] implemented the color coding technique as 
the FASPAD algorithm using dynamic programming, to address the NP-hard problem of 
discovering signaling paths inside biomolecular networks [Hüffner et al. 2007].  
Figure 5 outlines the algorithm pseudo code for DTSP detection. The steps in our algorithm 
are as follows: 
Step 1 - Discover high confidence paths  
Various types of evidence may be used to estimate confidence or reliability of each 
interaction in the network. The first step in the DTSP algorithm involves use of a heuristic 
approach to harvest a family of high-confidence paths in the PPI network, as shown in Figure 
4. The color coding algorithm is adapted to use the drug’s protein targets as fixed start nodes 
and proteins known to be associated with the toxicity as fixed end nodes. Toxicity-related 
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proteins may be members of pathways associated with the toxic phenomenon and can be 
identified from published literature as well as pathway annotation databases. 
ALGORITHM: DTSPDETECTION(G = (V,E), KEGGPaths ToxD, start, dest) 
For each Drug D Є ToxD 
% Find high confidence paths: length 3 to 10 for each drug 
For Pathlength = n : m 
 GR = FindHiConfPaths(G=(V,E), start, dest , NumPaths , %similarity , Pathlength) 
End 
% Compute edge centrality of each interaction in the network of high confidence paths  
IEDGE = ComputeEdgeCentrality(GR) 
% Find paths with high edge centrality (DTSP candidates) 
P = FindMaxCentralityPaths(GR , IEDGE) 
% Permutation test to evaluate statistical significance of DTSPs 
For each path P
i
 Є P 
 For permutations = 1: p 
   Assign RandomEdgeWeights(P
i
) 
   ComputePathScore(P
i
) 
 End 
P
SIG
 = computePval(P
i
) 
KEGG
annot 
 = FindSigPathways(P
SIG
) 
End 
% Find statistically significant KEGG Pathway association for DTSPs  
 Function KEGG
annot 
 = FindSigPathways(P
SIG
) 
   ES
path
 = CalculateEnrichScore(PathProtAnnotations, KEGGPaths) 
   KEGG
annot
 = ComputeSig(PathProtAnnotations, ES
path
, Permutations) 
  Return KEGG
annot
  
Return P
DTSP
 , KEGG
annot
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Figure 5 (continued) 
Pseudocode variable definitions: 
ToxD - Set of Drugs known to cause the toxicity 
D - a drug known to cause the toxicity 
start – Set of Drug Target Proteins (start nodes for signaling path detection) 
dest – Set of End nodes for the color coding algorithm 
NumberPaths – Input parameter for color coding, specifying the maximum number of 
paths to be discovered. 
%similarity – Threshold for the maximum allowed % similarity between two discovered 
paths. 
Pathlength – Input parameter to algorithm, specifying the length of each detected path. 
P – Set of high edge centrality paths discovered for a drug. 
Pi - a member of the path set P. 
PSIG – Set of statistically significant paths or DTSPs. 
PathProtAnnotations – KEGG pathway annotations for proteins inside DTSPs 
KEGGPaths – Set of canonical KEGG pathways and associated proteins. 
ESpath – Enrichment Score for a particular KEGG pathway 
KEGGannot – Set of KEGG pathways associated with proteins involved in DTSPs. 
Figure 5.  Algorithm pseudocode for DTSP Detection 
As an example, proteins involved in hematopoiesis could be considered as end-nodes when 
discovering paths relevant to blood disorders. 
 Edge probabilities represent the strength of evidence for each interaction in the PPI 
network and detect paths that maximize the product of edge probabilities. Strength of evidence 
can be based on the amount and type of evidence available to verify the existence of each edge 
or interaction. Types of evidence may include experimental observation, consensus among 
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multiple databases, evidence gathered from research literature using text mining or gene-based 
analysis like gene fusion or neighborhood analysis and approaches similar to those used 
traditionally as ‘guilt by association’ (reviewed in chapter 2). The color coding algorithm is 
then applied to this network, to discover paths that consist of high confidence interactions. The 
resulting family of high confidence paths is used in the subsequent steps to identify possible 
drug-toxicity signaling paths, as described in step 2.  
 Given the fact that the problem of discovering all paths between two nodes in a large 
network is NP-hard (Non-deterministic polynomial-time hard), a heuristic approach is 
developed for detection of high confidence paths, as described in section 3.2. The color coding 
algorithm, as implemented by Hüffner et al. takes various input parameters, including the 
length of detected paths, the maximum threshold for similarity between two discovered paths, 
the total number of paths to be discovered and the start/end nodes for detected paths in the 
network.  
Step 2 -  Compute edge weights using an appropriate measure 
The family of high confidence paths discovered in step 1 constitute theoretical paths, some 
of which may be actual drug toxicity signaling paths. Others may just be topological interaction 
chains that link the drug’s protein targets to toxicity-related proteins in the network without 
being actually involved in the mechanism of the toxicity. Identification of drug-toxicity 
signaling paths from among these high confidence paths, therefore requires a criteria that is  
a. Relevant for discovery of drug toxicity signaling paths from a toxicological perspective 
and  
b. Enables mining of the network of high confidence paths to yield protein ‘hot spots’.  
In order to accomplish this, two novel edge weighting criteria have been proposed and 
implemented as a part of this thesis. The first approach applies background knowledge of a set 
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of drugs known to cause the toxicity to discover proteins that are most central to linking a set of 
drugs to toxicity-related proteins via their respective protein targets. 
 
Figure 6.  Edges or protein interactions that are highly central to the detected set of paths are 
assigned a higher relevance score. 
This criterion for edge weighting, termed as the edge centrality measure, is described in 
detail in section 3.2. The second approach uses drug-specific gene expression data to compute 
edge weights that reflect the extent to which various protein interactions in the high confidence 
graph involve genes that are highly differentially regulated after drug administration. The gene 
expression measure and findings from its application have been described in detail in chapter 4. 
Each interaction in the smaller network of high confidence paths is weighted using one of 
the measures described above and the resulting network is used to detect drug-toxicity 
signaling path candidates in step 3.  
Step 3 - Automated Signaling Path (DTSP) Detection 
Step 3 in our algorithm uses the network of reliable paths as its starting point, with each 
edge being assigned a new weight using one of the two measures described in step 2. As shown 
in Figure 6, the color coding technique is re-applied to this weight graph so as to detect drug 
toxicity signaling path (DTSP) candidates or paths with a high product of edge weights. The 
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input parameters to the color coding algorithm remain the same. At this step in the algorithm, 
the detected path candidates are yet to be evaluated for statistical and biological significance.  
Step 4 - Evaluate statistical significance of detected paths  
Evaluation of statistical significance for detected  network paths has been carried out 
previously using a randomized network approach [Lindfors et al. 2009]. Briefly, edge weights 
in our network are randomly shuffled across the network to create a simulated edge weighted 
PPI network with the same overall distribution of edge weights. The ranking statistic (product 
of edge probabilities) is then calculated for each path detected in step 3 above. The simulation 
is repeated 10,000 times to yield a distribution of the statistic for each path. The threshold for 
statistical significance of p < 0.01 is applied after correcting for multiple test comparisons 
using an appropriate correction measure.  
Step 5 - Evaluate the biological relevance of detected paths  
Functional attributes of the set of path proteins (common to DTSPs across the set of drugs) 
and their ability to modulate disease pathways can be analyzed using geneset enrichment 
methods. Subramaniam et al. have proposed and implemented the geneset enrichment analysis 
(GSEA) approach, aimed at extracting biological insight from genome wide information 
[Subramanian et al. 2005]. Briefly, given an a priori defined set of genes S (e.g. pathways 
associated with DTSP proteins), the goal of GSEA is to determine whether the members of S 
are randomly distributed throughout L (e.g. the set of all proteins in the network) or primarily 
found at the top (among the most commonly occurring pathway annotations associated with 
DTSP proteins) or bottom (among the rarely occurring pathways associated with DTSP 
proteins). The expectation would be that pathways related to the phenotypic distribution (e.g. 
pathways related to the set of detected drug toxicity signaling paths) will tend to show the latter 
distribution. As described by Subramaniam et al. [Subramanian et al. 2005], there are three key 
elements of the GSEA method: 
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Step 1: Calculation of Enrichment score. The enrichment score is the maximum deviation 
from zero encountered in a random walk, when a running-time statistic is increased if a gene in 
S (i.e. having a particular functional/pathway annotation) is encountered by walking down the 
list in L (i.e. the list of all common path proteins in DTSPs for drugs known to cause the 
toxicity) and decreased if the gene encountered is not in S. The Enrichment Score (ES) 
corresponds to a weighted Kolmogorov-Smirnov-like statistic. 
Step 2: Estimation of significance level of ES. The statistical significance of ES is estimated 
using an empirical phenotype-based permutation test procedure. The phenotype labels are 
permuted and the ES is recomputed for multiple permutations to generate a null distribution. 
The confidence intervals for this distribution are computed and the actual ES is compared to 
these thresholds to establish statistical significance. 
Step 3: Adjustment for Multiple Hypothesis Testing.  When the entire set of pathway 
annotations is evaluated for statistical significance for all path proteins, the estimated 
significance level is adjusted to account for multiple hypothesis testing.    
Geneset enrichment analysis can point to biological processes that may be modulated 
downstream from the drug’s target proteins as reflected through the identification of proteins 
involved in DTSPs. Statistically significant enrichment of specific pathways and functional 
annotations among the set of DTSP proteins may highlight their relevance to the drug-induced 
toxicity of interest.  
3.2 Discovering DTSPs for drug-induced non-immune Neutropenia 
3.2.1 Non-immune Neutropenia: considerations for selecting the toxicity under 
evaluation 
 In order to evaluate the ability of our algorithm to detect toxicity-specific proteins inside a 
PPI network, compounds known to induce Neutropenia were considered. Neutropenia resulting 
from drug administration can be fatal when severe. In the United States, labels of over 40 
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currently marketed prescription drugs include a warning of a risk for neutropenia and/or 
agranulocytosis [Multiple 2005]. Neutropenia can be a ‘type A’ (dose-dependent, typically 
associated with the drug’s mechanism of action) or a ‘type B’ (not related to pharmacological 
action, typically an immunological or hypersensitivity reaction) adverse effect [Edwards and 
Aronson 2000]. The thesis uses non-immune mediated (type A) neutropenia to evaluate the 
approach because our algorithm leverages information on the drug’s target proteins that may be 
directly associated with the drug’s mechanism of action. 
3.2.2  Drugs, Drug Targets and Toxicity-related proteins 
Our algorithm utilizes existing knowledge about drugs that are known to be associated with 
the toxicity of interest. Three types of evidence were used to create a list of drugs known to be 
associated with non-immune neutropenia. First, literature mining was performed on Pubmed 
abstracts to parse sentences involving neutropenia and a drug term. The drugs were ranked by 
frequency of co-occurrence with neutropenia or one of its subtypes and the list was manually 
curated to remove irrelevant associations. Second, the Comparative Toxicogenomics database 
[Mattingly et al. 2006] was searched to create a list of compounds associated with neutropenia. 
Third, a toxicologist reviewed the combined list from both analyses to provide a list of drugs 
associated with non-immune neutropenia. Table 3 shows a list of drugs identified with this 
approach. Information from the STITCH database was used to identify each drug’s target 
proteins [Kuhn et al. 2008]. STITCH database provides chemical-protein interaction 
information integrated from multiple public databases, including DrugBank {Wishart, 2006 
#104}, SuperTarget and Matador {Gunther, 2008 #127} . 
As per our definition of DTSP, proteins associated with the pathophysiology of interest had 
to be included as ‘end’ nodes in our path detection algorithm. A review of literature pertaining 
to hematopoietic regulation reveals the key role of a set of proteins involved in neutrophil 
production and maturity [Kaushansky 2006, von Vietinghoff and Ley 2008, Daniel et al. 2009]. 
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These proteins are involved in lineage commitment to a specific cell type during the 
differentiation of hematopoietic stem cells into one of the multiple blood cell types, including 
platelets, erythrocytes, monocytes, neutrophils, T cells, NK cells and B cells. In addition to 
their relevance to neutrophil biology, some of these proteins (e.g. CFU-GM) have recently been 
proposed as possible early markers of bone marrow toxicity [Pessina et al. 2005]. 
The proteins listed in Table 4 were therefore considered as ‘end’ nodes in the PPI network. 
3.2.3  Rationale for use of an Edge Centrality Measure 
 Consider a hypothetical situation where all high confidence paths discovered in step 1 of 
the algorithm have exactly one interaction in common. This interaction could be considered the 
most central to achieving topological connectivity between the drug’s targets and the toxicity 
of interest because all reliable paths discovered in step 1 involve this protein interaction. The 
interacting proteins would be of interest from a biological perspective because their function 
could yield insights into toxic mechanisms that link the drug to its adverse effect. Edge 
centrality is important from a biological perspective because interactions common to high 
confidence paths across toxicity-inducing drugs may point to common mechanisms of toxicity. 
TABLE 3. Protein ‘end nodes’ for path detection. 
Ensembl Protein ID Description HGNC symbol 
ENSP00000225474 Granulocyte colony-stimulating factor Precursor  CSF3 
ENSP00000228280 Kit ligand Precursor (C-kit ligand)(Stem cell factor) KITLG 
ENSP00000231454 
Interleukin-5 Precursor (IL-5)(T-cell replacing 
factor)  
IL5 
ENSP00000296871 
Granulocyte-macrophage colony-stimulating factor 
Precursor (GM-CSF)  
CSF2 
 
 
 
38 
 
Edge centrality in this context, is defined as the extent to which a particular edge is involved 
in all drug-toxicity signaling paths for a particular drug. As a general case across many drugs 
that cause the same toxicity,  edge centrality of each interaction can be computed to identify 
those edges in the network that are most central to linking the drug’s targets to its toxicity of 
interest, as shown in Figure 7. Edge centrality of an edge e is defined as the number of reliable 
paths that pass through e. Each edge in the set of high confidence paths is assigned a weight 
equal to its edge centrality. 
TABLE 4. Drugs associated with Non-immune Neutropenia  
Drug Therapeutic category[DrugBank] 
Vancomycin Anti-Bacterial Agents , Glycopeptide antibacterials 
Zidovudine 
Anti-HIV Agents, Antimetabolites, Nucleoside and Nucleotide 
Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitors 
Econazole Antifungal Agents 
Miconazole Antifungal Agents 
Ketaconazole Antifungal Agents 
Isoniazid Antitubercular Agents, Fatty Acid Synthesis Inhibitors 
Rifampicin 
Antitubercular antibiotics, Antituberculosis Agents,Enzyme 
Inhibitors,Leprostatic Agents,Nucleic Acid Synthesis Inhibitors 
Clotrimazole Local Anti-Infective agents,Antifungal Agents, Growth Inhibitors 
Doxorubicin Antibiotics, Antineoplastic Agents 
Methotrexate 
Abortifacient Agents, Abortifacient Agents, Nonsteroidal 
Antimetabolites, Antimetabolites, Antineoplastic Agents, 
Antirheumatic Agents, Dermatologic Agents, Enzyme Inhibitors, 
Folic Acid Antagonists, Immunosuppressive Agents, Nucleic Acid 
Synthesis Inhibitors 
Etoposide 
Antineoplastic Agents, Phytogenic Nucleic Acid Synthesis 
Inhibitors 
Irinotecan 
Phytogenic Antineoplastic Agents, Enzyme Inhibitors, 
Parasympathomimetics, Prodrugs, Radiation-Sensitizing Agents 
Paclitaxel Phytogenic Antineoplastic Agents, Tubulin Modulators 
Tamoxifen 
Hormonal Antineoplastic Agents, Bone Density Conservation 
Agents, Estrogen Antagonists, Selective Estrogen Receptor 
Modulators 
Vinblastine Phytogenic Antineoplastic Agents, Tubulin Modulators 
Promazine 
Antiemetics, Antipsychotic Agents, Antipsychotics, Dopamine 
Antagonists, Neuroleptics, Phenothiazines 
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Table 4 (continued)  
Desferrioxamine Chelating agent, Iron Chelating Agents, Siderophores 
Furosemide Diuretics, Sodium Potassium Chloride Symporter Inhibitors 
HCTZ 
Antihypertensive Agents, Diuretics, Sodium Chloride Symporter 
Inhibitors 
  
 
This smaller network of reliable paths is then used to detect drug-toxicity signaling paths. In 
step 2 of our algorithm the edge centrality of each interaction/edge in the family of high 
confidence paths is computed. 
 
3.2.4  DTSP algorithm implementation 
The color coding algorithm was adapted so that it could be applied towards discovery of 
signaling paths relevant to the toxicity of interest. Toxicity relevance for detected paths was 
achieved through use of hematopoiesis-related proteins (shown in Table 3) as destination nodes 
in the algorithm. Drug relevance for detected paths was achieved through use of drug target 
proteins as ‘source’ nodes in the algorithm. The primary source of protein interaction data was 
the STITCH database (http://stitch.embl.de/). All protein-protein interactions from the STITCH 
database were downloaded and the human subset was used as our PPI network.  
Details on the STITCH database and calculation of combined score for confidence of each 
edge have been published elsewhere [Kuhn et al. 2008]. Briefly, a consolidated set of 
chemicals was derived from PubChem and relations between chemicals were derived from 
similar activity profiles in the NCI60 cell lines, from pharmacological actions assigned to 
chemicals in the Medical Subject Headings (MeSH) and from the literature. In order to link the 
derived chemical-chemical associations to the protein world, a variety of databases of 
chemical-protein interactions were imported.  Experimental evidence of direct chemical-protein 
binding was derived from the PDSP Ki Database and the protein data bank [Berman et al. 
2000]. The STITCH database contains interaction information for over 68000 chemicals, 
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including 2200 drugs, and connects them to 1.5 million genes across 373 genomes and their 
interactions contained in the STRING database [Jensen et al. 2009]. 
 
Figure 7.  STRING Database: Evidence types used to confidence score for each interaction 
(reproduced from Jensen et al. 2009 [Jensen et al. 2009]) 
 
Many of the protein-protein interactions in the STRING database are imported from other 
databases but STRING also contains a large body of predicted associations that are produced 
de novo. Completely sequenced genomes are periodically imported and searched for three 
types of genomic context associations:  
a. Conserved genomic neighborhood: The conservation of proximity of genes along the 
genome between distantly related species may predict interaction between the protein 
products {Dandekar, 1998 #581}. 
b. Gene fusion events: Some interacting protein pairs are encoded by two independent 
genes in some organisms whereas they are encoded by a single gene in other organisms. 
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Knowledge of gene fusion events may therefore be used to ascertain whether two 
proteins may be interacting with each other [Valencia and Pazos 2003]. 
c. Co-occurrence of genes across genomes : Similar Loci for genes corresponding to a 
protein pair across genomes may point to a possibility of interaction. 
All three searches aim to identify pairs of genes which appear to be under common selective 
pressures during evolution (more so than expected by chance), and which are therefore thought 
to be functionally associated. Another important source of protein association information is 
published literature. As shown in Figure 8, STRING database assigns confidence score to 
interactions based on systematic extraction of associations from PubMed, by searching for 
recurrent co-mentioning of gene names in abstracts. This search relies on gene names and 
synonyms parsed from SwissProt as well as from organism-specific databases. It utilizes a 
benchmarked scoring system based on the frequencies and distributions of gene names in 
abstracts. Finally, protein-protein interactions are also derived from functional genomics data: 
evidence of co-regulation of genes across diverse experimental conditions is imported from the 
ArrayProspector server [Jensen et al. 2004]. 
The command-line version of FASPAD implementation [Hüffner et al. 2007] was used to 
discover high confidence paths in the PPI network using a heuristic approach. As a first step in 
the algorithm, signaling paths were detected with maximum product of path reliabilities for 
path lengths up to 10. The rationale for selection of a maximum path length of 10 was based on 
the observation that the number of new proteins involved in discovered paths decreased 
drastically as the path length approached 10, as shown in Figure 9. For each path length, 100 
high confidence paths were harvested to detect a total of 800 candidate signaling paths for each 
drug. FASPAD parameters were set so that there was no more than 70% similarity between 
two paths of the same length. For the second step in our algorithm, the network created from 
high confidence paths was used to compute the edge centrality value for each interaction. As 
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described in section 3.1, the edge weights were then re-assigned to each interaction using its 
edge centrality value, so that the value on each interaction represented the extent to which the 
interaction was central to paths that connect the drug target proteins to toxicity-related proteins 
in the network. The third step in the algorithm involved detection of paths with high edge 
central interactions, or the set of candidate ‘Drug – Toxicity signaling paths’ for each drug. The 
color coding algorithm was applied again, with the same parameters as earlier but with edge 
weights reassigned based on edge centrality calculation for each interaction.  
The resulting set of signaling paths was then evaluated for statistical significance as 
described in section 3.1. The product of edge weights for each path was used as the test 
statistic. For 20,000 random permutations of edge weights inside the network, the product of 
edge weights for each discovered path was calculated. Paths were then filtered using a p < 0.01 
threshold and only paths with statistically significant value were retained. This process was 
repeated for each drug listed in Table 4. Finally, Geneset Enrichment analysis (GSEA) 
implemented in WebGestalt [Zhang et al. 2005] was run to identify significant KEGG pathway 
associations for DTSP proteins. 
Briefly, the procedure calculated a ratio enrichment score for each KEGG pathway as k/ke, 
where k was the actual number of genes in the DTSP set of proteins that belonged to a 
particular KEGG pathway and ke is the expected number of genes for that pathway. Using a 
statistical significance threshold of p<0.01 for hypergeometric test and Bonferroni multiple 
testing correction, a set of canonical pathway associations for each drug were identified.  
3.3 Results and Discussion 
3.3.1  Impact of the signaling path detection approach 
A key motivation for this approach was to evaluate whether the huge network of human 
protein-protein interactions can be condensed to a small set of proteins that may constitute a 
‘bottleneck’ linking drug targets with the toxicity-related end nodes in the network. In order to 
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evaluate this, we compared the total number of immediate neighbors of our end nodes with the 
number of immediate neighbors that were involved in at least one DTSP. At level 1 (immediate 
neighborhood of toxicity-related proteins), we found 2337 proteins connected to the four ‘end 
nodes’ related to non-immune neutropenia. All of these immediate neighbors could 
theoretically be involved in paths terminating in end nodes. However, for the non-immune 
neutropenia causing drugs analyzed in this study, only 227 proteins out of the 2337 were found 
to be involved in a drug-toxicity signaling path. Within the set of immediate neighbors for 
toxicity-related proteins, these 227 proteins appeared to be more relevant to understanding the 
mechanism of non-immune neutropenia compared to the rest. Taking this observation to the 
next level of connectivity, out of 16339 proteins that were linked to the 2337 immediate 
neighbors, our algorithm found 270 proteins in DTSPs detected for drugs analyzed. The value 
of our approach was evident from its ability to identify a smaller set of proteins that were 
relevant to both the toxicity of interest as well as the drugs known to be associated with the 
toxicity. 
 
3.3.2  Path length heuristic and discovery of new proteins 
One important consideration in our algorithm was the choice of path length when harvesting 
signaling paths. As the path length increased towards 10, longer paths seemed to be created 
using proteins involved in shorter paths. This is demonstrated in Figure 9, where the number of 
new proteins involved in discovered paths decreases substantially as the path length increases. 
To the extent that the algorithm is aimed at identification of protein/s relevant to the toxicity, 
there seems to be limited value in detecting paths of higher lengths. This is an aspect of this 
algorithm that needs to be investigated in more detail. 
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Figure 8.  As the path length increases towards 10, the number of discovered paths 
involving additional proteins decreases towards zero 
 
3.3.3   Network ‘hotspots’ and their toxicological relevance  
As conceptually visualized in Figure 7, proteins involved in at least one DTSP for all drugs 
get a high interestingness score due to their ability to provide topological connectivity between 
a target protein and a toxicity-related protein for all drugs that are known to be associated with 
the toxicity. We therefore analyzed the list of DTSPs to find proteins that were common across 
all drugs analyzed in this study. As shown in Figure 10, 119 proteins were involved in a DTSP 
for a single drug, 12 proteins were common to 4 Drugs (i.e. involved in one or more DTSPs for 
four drugs) and 9 proteins were found to be involved in one or more DTSPs for all drugs. Table 
5 lists the nine proteins that occur in one or more DTSPs across all drugs. 
A brief summary of their relevance to non-immune neutropenia is provided below –  
A genetic variant of CSF2RB (Ensembl id: ENSP00000262825) has been patented in its 
application as a marker associated with adverse hematological response to drugs [Athanasiou 
and GERSON 2006]. GM-CSF exhibits a number of overlapping biological activities in 
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hematopoiesis, which are all mediated via binding of GM-CSF to the GM-CSF receptor 
[Barreda et al. 2004]. The STAT3 (signal transducer and activator of transcription 3, acute-
phase response factor) protein (Ensembl id: ENSP00000264657) plays a key role in apoptosis 
and cell differentiation. Deletion of STAT3 in rats has been shown to cause abnormalities in 
myeloid cells [Welte et al. 2003]. 
 
 
Figure 9.  Plot shows the number of proteins that occur at least once across various drugs in 
the analysis set. 
The Janus Kinase JAK1 (Ensembl id: ENSP00000294423) and JAK2 (Ensembl id: 
ENSP00000371067) pathways in addition to the STAT pathway constitute a major signaling 
mechanism engaged by the G-CSFR (Granulocyte Colony Stimulating Factor) receptor. When 
activated by the GCSFR, Jak tyrosines phosphorylate STAT complexes which then translocate 
to the nucleus where they activate transcription [Touw and Bontenbal 2007]. The Tyrosine 
protein phosphatase non-receptor type 6, PTPN6 protein (Ensembl id: ENSP00000326010) is a 
key regulator of neutrophil apoptosis [Simon 2003]. The growth factor receptor bound protein 
2 (Ensembl id: ENSP00000339007) functions as an adapter protein in the MAPK transduction 
pathway which plays a key role in hematopoiesis [Geest and Coffer]. The SHC-transforming 
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protein 1 (Ensembl id: ENSP00000357432) is another signaling adapter that couples activated 
growth factor receptors to MAPK signaling pathway.  
The KIT stem cell precursor (Ensemble id: ENSP00000370749) is the receptor of the stem 
cell factor that is directly involved in myeloid cell differentiation. Finally, the Tumor Necrosis 
Factor precursor (Ensemble id: ENSP00000372790) is a cytokine that binds to tumor necrosis 
factor (TNF) receptor. TNF may have inhibitory effects on granulocyte-macrophage 
progenitors and on committed and primitive hematopoietic progenitors in vitro [Drutskaya et 
al. 2005]. 
TABLE 5. List of proteins that occur in at least one DTSP across all analyzed Drugs. 
Protein  
Ensembl Id 
HGNC 
Symbol Name 
Biological 
relevance 
ENSP00000262825 CSF2RB 
Colony Stimulating 
Factor Receptor, Beta 
Barreda et al. 
2004 [Barreda et 
al. 2004] 
ENSP00000264657 STAT3 
Signal Transducer and 
Activator of 
transcription 
Welte et al. 
2003[Welte et al. 
2003] 
ENSP00000294423 JAK1 Janus Kinase 1 
Touw et al. 
2007[Touw and 
Bontenbal 2007] 
ENSP00000326010 PTPN6 
Tyrosine Protein 
phosphatase type 6 
(HCP, PTP1C) 
Simon 
2003[Simon 
2003] 
ENSP00000339007 GRB2 
Growth Factor Receptor 
Bound 2  
Geest et al. 
2009[Geest and 
Coffer 2009] 
ENSP00000357432 SHC-1 
SHC-transforming 
protein 1  
Geest et al. 
2009[Geest and 
Coffer 2009] 
ENSP00000370749 
KIT 
precursor Stem Cell precursor 
Kaushanky 
2006[Kaushansky 
2006] 
ENSP00000371067 JAK2 Janus Kinase 2 
Touw et al. 
2007[Touw and 
Bontenbal 2007] 
ENSP00000372790 
TNF 
precursor 
Tumor Necrosis Factor 
precursor  
Drutskaya et al. 
2005[Drutskaya 
et al. 2005] 
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 3.3.4  Elucidating class-specific mechanisms of toxicity 
In order to understand whether proteins involved in paths discovered for one class of drugs 
were different from another, we compared proteins common to anti-infective and anti-cancer 
DTSPs i.e. proteins involved in one or more DTSPs for all drugs that belong to the same 
therapeutic class. A set of 12 proteins were found to be involved in one or more DTSPs for all 
anti-cancer drugs. A different set of 10 proteins were found to be involved in one or more 
DTSPs for all anti-infective drugs. Geneset enrichment analysis revealed distinct biological 
processes being regulated by each set. We found that the ‘anti-infective’ set of proteins were 
also involved in biological processes like response to bacterial stimulus. This observation 
seems to imply that anti-infective mode of action may be the desirable action for drugs in this 
class, but proteins involved in anti-infective related processes also link the drug targets and/or 
the indication to hematopoiesis-related proteins in the network. The observation also seems 
important in light of the fact that manifestations of agranulocytosis are secondary to infection 
[Flanagan and Dunk 2008].  
3.3.5  Pathway Association for DTSP proteins 
The robustness of a phenotype may be understood in terms of alternative compensatory 
signaling routes inside complex biomolecular networks. To this end, proteins involved in the 
set of DTSPs for each drug may yield insights into downstream effects of the drug on multiple 
biological and disease pathways. Geneset enrichment provided a set of KEGG pathways with 
high ratio enrichment score for each drug. Using this approach for each drug, we identified a 
set of KEGG pathways that were statistically overrepresented in DTSPs for that drug. Table 6 
shows a list of KEGG pathways that were overrepresented for all drugs in this analysis.  
A key observation from enrichment analysis was that proteins associated with cancer-
related pathways were found within DTSPs discovered for all drugs associated with non-
immune neutropenia in this analysis. This finding applied to all drug classes analyzed with our 
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algorithm, including anti-cancer, anti-infective as well as other disease-related drugs. Though 
an observation made on a small number of drugs, this is in line with the clinical observation 
that cytotoxic cancer treatments predispose patients to clinically significant changes in 
neutrophil counts, often leading to severe neutropenia [Crawford et al. 2004]. Neutrophils 
being the first line of defense against infection and as the first cellular component of the 
inflammatory response to nascent infections, it is conceivable that proteins involved in 
inflammatory response and immune system disorders are also members of drug-toxicity 
signaling paths discovered using our algorithm.  
TABLE 6. Pathway Association for DTSP proteins  
KEGG pathway Id KEGG Pathway Name 
hsa05221 Acute myeloid leukemia 
hsa04920 Adipocytokine signaling pathway 
hsa04662 B cell receptor signaling pathway 
hsa04062 Chemokine signaling pathway 
hsa05220 Chronic myeloid leukemia 
hsa05210 Colorectal cancer 
hsa04060 Cytokine-cytokine receptor interaction 
hsa05213 Endometrial cancer 
hsa05120 Epithelial cell signaling in Helicobacter pylori infection 
hsa04664 Fc epsilon RI signaling pathway 
hsa04510 Focal adhesion 
hsa05214 Glioma 
hsa04910 Insulin signaling pathway 
hsa04630 Jak-STAT signaling pathway 
hsa04010 MAPK signaling pathway 
hsa04650 Natural killer cell mediated cytotoxicity 
hsa04722 Neurotrophin signaling pathway 
hsa05223 Non-small cell lung cancer 
hsa05212 Pancreatic cancer 
hsa05200 Pathways in cancer 
hsa05215 Prostate cancer 
hsa05211 Renal cell carcinoma 
hsa04660 T cell receptor signaling pathway 
hsa04620 Toll-like receptor signaling pathway 
hsa04930 Type II diabetes mellitus 
49 
 
3.4 Limitations 
This study was aimed at understanding downstream regulation of drug-induced toxicity at a 
‘systems’ level. Improvements on the proposed algorithm are certainly possible. First, we 
mined a non-directional PPI network for signaling paths. This implies that directionality of the 
interaction chains cannot be inferred from this analysis. Some background knowledge of the 
signaling cascade from the CSF receptor to activation of Colony Stimulating factor (CSF) 
suggests that proteins like JAK1, JAK2 and STAT3 are mediators of CSF activation but this 
cannot be concluded from our analysis. Second, we have used a range of path lengths and the 
maximum number of detected paths as parameters. 
In Figure 9, we have shown that the choice of heuristic path length seems appropriate. 
However, the choice of maximum paths discovered needs further investigation. 
Further analysis could reveal the extent to which the set of detected paths covers the 
available topological space. Further work is also needed to incorporate additional evidence, 
gene expression data, for example, to identify putative signaling paths from among the larger 
set we have discovered through this analysis. Integration with gene expression data may also 
reveal ‘dose-specific’ paths that reflect pharmacodynamic changes after drug administration. 
We believe that the use of multiple sources of evidence to assign interaction confidence scores 
may have resulted in fewer false negatives and that, integration with gene expression data may 
also reduce the potential for false negatives in our analysis. Finally, a large set of drugs known 
to induce non-immune neutropenia needs to be analyzed, preferably from a wider variety of 
therapeutic categories, to understand the specificity and sensitivity of our approach. 
3.5 Conclusions 
This study explored downstream effects common to drugs known to induce non-immune 
neutropenia.  Using our approach, we have identified proteins that constitute ‘bottlenecks’ in 
interaction chains that link a neutropenia-inducing drug with toxicity-related endpoints. Further 
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analysis is required to identify pathways involved in pathophysiology of non-immune 
neutropenia for various drug classes. The edge centrality based approach provides an 
alternative to other approaches that can be applied at the systems level, either using local or 
global properties of PPI networks. We have demonstrated the value of our approach using non-
immune neutropenia as a test case. The algorithm may be applied towards detection of protein 
interaction hotspots for any toxicity where the drugs known to induce the toxicity and the 
physiological processes involved in the toxic mechanism are known. 
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CHAPTER 4: INTEGRATING PROTEIN INTERACTION AND GENE 
EXPRESSION INFORMATION TO GAIN INSIGHTS INTO TOXICITY 
MECHANISMS 
 
In chapter 3, the drug-toxicity signaling path (DTSP) algorithm was used to  identify 
toxicity-related hotspots inside protein interaction networks through a combination of color 
coding and edge centrality as a measure for filtering detected paths [Desai et al. 2011]. The 
approach relied on background knowledge of a set of drugs and proteins related to the drug-
induced toxicity. One of the recognized limitations of the edge-centrality based approach is its 
inability to leverage dynamic drug-specific gene expression data to further inform the filtering 
of detected signaling paths. This chapter extends the earlier approach by incorporating a gene 
expression-based measure for filtering discovered paths based on analysis of gene expression 
data collected in vitro after treatment with the set of drugs under consideration. The resulting 
set of path proteins is analyzed, leading to a biomarker panel that may be used for screening of 
drug candidates. 
All steps involved in the drug-toxicity signaling path detection algorithm as well as 
implementation of the algorithm for non-immune neutropenia have been described in section 
3.1 and 3.2. These details will therefore, not be repeated in this chapter. The advantages of 
using a gene-expression based measure are described in section 4.1 and implementation of the 
measure is described in section 4.2. Section 4.3 discusses results from the analysis, followed by 
Limitations and Conclusions in section 4.4 and 4.5 respectively. 
4.1 Advantages of using a gene-expression based measure 
As described in chapter 2, contextual information in the form of evolutionary conservation 
of expression patterns across organisms when used for guilt by association (GBA) analysis, has 
yielded functionally related groups of genes under homeostatic conditions  [Quackenbush 
2003]. Gene co-expression based GBA approaches have also looked for genes whose 
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expression patterns mimic those of known disease-associated genes[Walker et al. 1999]. While 
such approaches are useful for assigning disease association more generally, they may not be 
sufficient for identifying proteins associated with drug-induced toxicity. This is because genes 
discovered using such approaches may be located multiple levels downstream from protein 
targets of drugs associated with a particular toxicity.  
Integrating gene expression data with protein interaction networks has many advantages. 
First, to the extent that gene expression data can reflect dynamic changes that happen at various 
time points after drug administration, this could enable identification of signaling paths that 
consist of genes that are differentially expressed between treated and control conditions. 
Second, clustering expression data into groups of genes that share profiles is a proven method 
for grouping functionally related genes, but does not order pathway components according to 
physical or regulatory relationships [Steffen et al. 2002]. Protein Interaction information can 
complement gene expression data to help identify differentially expressed genes that may lie 
downstream from the drug’s known target proteins and upstream from the known toxicity-
related endpoints in the network. 
Commercial pathway analysis tools provide the ability to construct networks based on 
integration of evidence from multiple sources and the ability to analyze the resulting network 
using algorithms like shortest paths [Ekins 2006]. Drug administration perturbs the biological 
network at specific ‘nodes’ (referred to as drug target proteins) that may be several levels 
upstream from the toxicity-related ‘endpoints’ in the network. Mapping the cascade of proteins 
associated with drug response is therefore a central challenge in toxicity evaluation. 
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ALGORITHM: INTEGRATEEXPRESSION(G = (V,E), ToxD, startVert, dest) 
For each Drug D Є ToxD 
% Find high confidence paths: length 3 to 10 for each drug 
For Pathlength = n : m 
 GR = FindHiConfPaths(G = (V,E),startVert,dest, Paths ,%similarity, Pathlength) 
End 
% Compute Gene Expression Score for high confidence interactions (based on gene expression 
for interacting proteins) 
PathExpScore = ComputeIntExpScore(GR , D) 
% Detect signaling paths that maximize path differential expression score  
P = FindMaxDiffExpPaths(GR , PathExpScore) 
For permutations = 1: p 
 For each interaction P int 
Assign RandomEdgeWeights(P int) 
ComputePathScore(P) 
 End 
End 
PSIG = computePval(P) 
% Compute common pathproteins for each therapeutic category 
Pcancerprot = intersect (ProtsPSIG) 
Return PSIG , Pcancerprot 
 
Pseudocode variable definitions  (also refer to other variables defined in Figure 5): 
P – Set of paths with highest differential gene expression between treated and control. 
Pcancerprot – Path proteins found on DTSPs for anti-cancer treatments. 
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Figure 11 (continued) 
Function ComputeIntExpScore(GR , D) 
% Extract and Process Raw gene expression CEL files for n Treated samples and  
% m vehicle  scans for each Treated sample. Compute Average Expression Score for 
% each probeset and each protein. Finally, compute interaction expression score. 
 RawExp = GetCEL(D) 
 GCTExp = ExpressionFileCreator(RawExp,‘QuantileNorm’,’medianScale’, HgU.cdf) 
  For probesets = 1: pn 
  For each Experiment i 
  SampleExpScore(i) =  
  Return SampleExpScore 
   ProbesetExpScore = ln( ) 
   End 
  For each Path p in GR 
  For each protein i in p 
  ProtExpScore(i) = i np 
  End 
  IntExpScore(p) = i  
  Return IntExpScore 
Return IntExpScore 
 
Pseudocode variable definitions: 
RawExp – Raw CEL file data for a single sample. 
GCTExp – Matrix of probeset-Sample with expression values inside each cell. 
SampleExpScore  – Ratio of treated/control expr. values for all HT_HGU133 probesets. 
ProbesetExpScore  – Log ratio of average gene expression score across all samples 
ProtExpScore  – Average gene expression score for a protein based on mapped probesets. 
IntExpScore  – Interaction expression score, i.e. average differential expression score for 
interacting proteins 
 
Figure 10.  Algorithm Pseudocode for detecting Drug-Toxicity Signaling Paths using 
microarray data 
55 
 
4.2 Computing Edge weights using Gene Expression Measure 
Gene expression was used to identify paths that may be ‘active’ in the presence of a drug 
known to induce the toxicity. A differential gene expression measure was applied as follows – 
We hypothesized that the most relevant toxicity-related paths would consist of genes that 
showed high differential expression between treatment (with drugs associated with the toxicity) 
and control. In other words, if all proteins in a detected path consisted of genes that were 
unperturbed after treatment, that path was unlikely to be associated with the drug and its 
toxicity and would therefore be ranked lower with our algorithm. Also, the algorithm should 
consider the magnitude of up-regulation and down-regulation as equally important. So, a 2-fold 
up-regulation would be considered as important as a 2-fold down-regulation. We therefore, 
using principles inherent in a ranking measure proposed earlier [Zhang and Gant 2008], 
calculated the average absolute log ratio of treated vs. control for each protein in the set of 
reliable paths to assign weights for each interaction based on differential gene expression of 
proteins participating in that interaction. This smaller network of reliable paths was then used 
to detect drug-toxicity signaling paths in step 3 of the algorithm (described in section 3.1). 
To compute the gene expression measure, we downloaded gene expression CEL files from 
the connectivity map data provided by the MIT Broad Institute. Details of the connectivity map 
data have been published elsewhere [Lamb 2007]. Briefly, the connectivity map (also known as 
cmap) is a collection of genome-wide transcriptional expression data from cultured human cells 
treated with bioactive small molecules. Build 02 of this publicly available collection provides 
access to more than 7000 expression profiles representing 1309 compounds. For the 19 drugs 
analyzed in this study, we found 41 instances or experiments in the connectivity map 
collection, i.e. one or more treated samples (dose: 10µM, duration: 6 hours) and multiple 
vehicle scans in MCF7 cell lines. The ‘ExpressionFileCreator’ module in GenePattern was 
used to convert CEL files into gct format expression files [Reich et al. 2006]. Robust multichip 
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average (RMA) measure was used for conversion and quantile normalization was applied. The 
absolute average log ratio values were calculated for each probeset and each ensemble protein 
was assigned the average of all probesets that mapped to the protein. Mapping between affy 
probeset ids and ensemble ids was obtained from Ensembl database [Flicek et al. 2008]. Each 
edge or interaction in the network of reliable paths was then assigned the expression measure 
value as the average of absolute log ratio value for its interacting proteins. 
 The third step in the DTSP algorithm involved detection of paths consisting of high 
differential expression interactions, or the set of candidate ‘Drug – Toxicity signaling paths’ for 
each drug. We used the color coding algorithm again, with the same parameters as earlier but 
with edge weights assigned based on the gene expression measure for each interaction.  
4.3 Results and Discussion 
4.3.1 Difference in path proteins discovered with different measures 
In order to compare DTSPs discovered using differential gene expression with DTSPs 
discovered using edge centrality (published earlier [Desai et al. 2011]), the percentage 
difference in number of proteins involved in DTSPs obtained using the two measures was 
computed. An average of 45% proteins was different between the two measures. This finding 
seems to point to the fact that edge central proteins may not be substantially differentially 
expressed under treatment conditions. This may be attributable to the presence of alternative 
compensatory paths in protein interaction networks and the fact that highly edge central 
interactions by definition are likely to receive positive as well as negative regulatory inputs 
from a relatively large number of interactions. 
4.3.2  Toxicological relevance of detected paths 
As neutropenia is defined as a clinically significant reduction on neutrophils and as the end 
nodes (listed in table 3) in our algorithm are involved in neutrophil production, we considered 
paths that down-regulated the end nodes (treated < control) as more relevant than filtered paths 
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that up-regulated the end nodes  (treated > control), irrespective of the direction of regulation 
for intermediate nodes (nodes between the two end nodes for each path).  Also, to eliminate 
redundancy among down-regulated paths, we manually curated the list to identify the shortest 
path/s that down-regulated each end node. In other words, if there was one shorter path and one 
longer path that terminated in the same end node, we only considered the shorter path. The 
paths can be used to understand the relevant mechanisms of toxicity for a specific drug. For 
example, the highest ranked path for Clotrimazole may be interpreted as follows - 
In tissue samples treated with Clotrimazole, Cyp3A4 (node 1) inhibition may lead to down-
regulation of SRGN (node 2), the serglycin haematopoeitic cell granule proteoglycan which in 
turn, may serve as a mediator of granule mediated apoptosis [Ma et al. 2008]. SRGN down-
regulates the end node ‘KITLG’, stem cell factor (end node) that is able to augment the 
proliferation of both myeloid and lymphoid hematopoietic progenitors in bone marrow cells 
[Niemann et al. 2004].  
The above path was one of four paths for Clotrimazole, the other four having length four 
and ending in the second down regulated end node, IL5. 
The entire list of specific paths for each drug is pending further interpretation in the context 
of non-immune neutropenia. Table 7 shows a list of path proteins for each drug. 
4.3.3  Elucidating class-specific mechanisms of toxicity 
 In order to understand whether proteins involved in paths discovered for one therapeutic 
category of drugs were different from another, we compared proteins common within and 
between (involved in one or more DTSPs) anti-infective, anti-cancer and Other DTSPs. Only 
KITLG was common (>50%) within the three therapeutic categories suggesting some 
commonality of compounds that induce neutropenia irrespective of therapy area.  In addition, 
the following were common within a therapy area: IL5 and TNFa in anti-infective, BAX, 
CSF3, IL6 and IL8 in anti-cancer and FOS, IL6, IL8, JAK and JUN within other.    
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4.3.4  Potential neutropenia biomarkers  
 In addition to identifying common DTSPs, the data within Table 8 was evaluated to 
identify a potential neutropenia biomarker panel irrespective of therapy area.  KITLG was 
altered in 76% of all compounds evaluated and could be further investigated as a neutropenic 
biomarker.  Of the compounds where KITLG was not altered, TNFA was altered in the anti-
infective compounds and CSF3 (GM-CSF) in anti-cancer compounds.  Therefore, a biomarker 
panel containing at least KITLG, TNFA and CSF3 should be further investigated for detecting 
compounds that induce neutropenia. 
4.4 Limitations 
The DTSP algorithm and use of gene expression data has provided additional insights into 
signaling paths that may be down regulated in non-immune neutropenia. Other extensions may 
improve the algorithm further. Specifically, knowledge on protein localization and tissue 
specific protein expression may add further specificity to detected paths. Experimental 
validation of the proposed biomarker panel may provide evidence to support the use of the 
panel for screening drug candidates.  
4.5 Conclusion 
We have developed a new algorithm for detection of toxicity-related hotspots inside protein 
interaction networks and evaluated its ability to detect proteins relevant to non-immune 
neutropenia. This work has demonstrated that better network analysis algorithms can provide 
valuable insights into mechanisms of toxicity and at the same time, deliver potential 
biomarkers that may be experimentally validated and used as a tool for screening drug 
candidates. 
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TABLE 7. Proteins involved in DTSPs discovered for each drug 
Category Drug Path Proteins (HGNC Symbol) 
A
n
ti
-i
n
fe
c
ti
v
e
s 
Clotrimazole 
CD44, CYP3A4, GZMB, IFNG, IL5, IL11, 
KITLG, PRF1, SRGN 
Desferrioxamine 
CSF3, EPO, EPOR, FOS, IFNG, IL1B, IL5, IL6, 
IL8, JAK1, JUN, KIT, KITLG, MAPK11, 
MAPK14, RELA, SELP, STAT1, STAT6, TNFA 
Economazole ADCYP1, FOS, TNFA 
Isoniazid BOC, CA3, JAK2, KITLG, MPO, PTPN6 
Ketaconazole 
ABCB1, BCL2, CD79A, CCL2, CSF3, CYCS, 
EP300, EPOR, IL1A, IL2, IL4, IL5, IL6, IL6ST, 
IRS1, ITGAM, JAK1, JAK2, KIT, KITLG, LIF, 
MAPK8, PIK3R1, PRL, RELA STAT1, TNFA, 
TP53 
Miconazole BAX, CSF3, HMOX1, IFNG, KITLG, POR 
Rifampicin 
ABCB1, BCL2, CCND1, CCND3, CSF2, 
CYP1A2, GST3, IFNG, IL2, IL2RA, IL5, IL7, 
IL8, JAK1, JUN, MAPK1, MAPK8, NR3C1, 
NR0B2, RBL2, STAT1, STAT3, STAT5B, TNFA 
Vancomycin 
CCL5, CD4, IL1A, IL5, IL6, IL10, IL11, IL12B, 
JUN KITLG, STAT3, TNFA 
Zidovudine 
CD4, EPO, FOS, IL5, IL10, IL12A, JAK2 
KITLG, STAT3 
A
n
ti
-c
a
n
c
e
r1
 
Doxorubicin 
BCL2, CASP8, CSF3, FADD, IL4, IL6, IRS1, 
KIT, KITLG, MAPK1, PIK3R1, TNFA 
TNFRSF1A 
Etoposide 
ABL1, BAX, BCL2, BCL2L1, CASP3, CSF2RB, 
CSF3, DIABLO, EP300, IFNG, IL2, IL5, IL6, 
IL8, MAPK8, MDM2, PTPN6, RB1,STAT3 TP53 
Paclitaxel EPOR, FOS, IL12A, JAK2, KIT, KITLG 
Tamoxifen 
BAX, BCL2, CRH, CSF2, CSF3, FOS, IFNG, 
IL1A, IL2, IL3, IL5, IL6, IL8, JUN, KITLG, 
MAPK8, TGFB1, TNFA, TP53 
Vinblastine CD4, CSF3, IL8, IL10 
O
th
e
r 
Furosemide 
AGT, APAF1, BCL2, FOS, IL1B, IL2, JAK2, 
JUN, KITLG, LRP1, OXT, PPP1R12A, RB1, 
REN, RHOA, SERPINE1, SHC1, SLC12A2, 
SPP1, TNFA 
Hctz 
ACE, AGTR1, CSF2, EDN1, FOS, IL5, IL6, 
JAK2, JUN, KITLG, REN, SERPINE1, 
SLC33A1, SOCS3, STAT3 
Promazine 
CHRM1, CSF3, EGFR, HTR2C, IL3, IL6, JAK2, 
KIT, KITLG, PIK3CA, SHC1, STAT1 
1 – Irinotecan was also analyzed in this therapeutic category but did not yield statistically 
significant DTSPs. 
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TABLE 8. Percentage of compounds with altered gene expression levels in each 
therapeutic category 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% 
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CHAPTER 5: DTSP ALGORITHM - COMPARATIVE EVALUATION 
 
Chapters 3 and 4 describe two unique analytical approaches for detecting signaling paths 
and toxicity hotspots inside large protein interaction networks. While the edge centrality 
approach (outlined in chapter 3) utilizes information on path involvement and edge centrality 
for each protein in the network, the gene expression integration approach (outlined in chapter 
4) leverages information on dynamic, drug-specific changes that occur inside the network as a 
result of drug administration, as measured using in vitro gene expression experiments. This 
chapter describes two implementations aimed at comparative evaluation of the DTSP approach. 
The first evaluation compares paths detected for the set of drugs known to cause non-immune 
neutropenia with another set of paths, discovered for drugs NOT known to cause drug-induced 
neutropenia. The second evaluation compares both DTSP algorithms with the current standard 
approach for biomarker identification in toxicogenomics – namely, microarray data analysis. 
Section 5.1 outlines the rationale for comparison of results with a ‘control’ set of drugs (i.e. 
drugs not known to cause non-immune neutropenia) and compares/contrasts results for the two 
set of drugs. The DTSP algorithm described in chapters 3 and 4 was used on this set of drugs 
along with the gene-expression based measure for assigning edge weights. Description of the 
algorithm implementation is therefore, not repeated in this chapter. 
5.1 Comparison: Toxicity-inducing Drugs vs Control Drugs 
5.1.1 Analysis Methods 
Biological changes inside the network may be caused by many different external stimuli. A 
set of biological changes may lead to multiple phenotypes. For example, an administered drug 
and an environmental allergen may both cause an up-regulation in inflammation-related 
pathways inside the network and this in turn, could lead to many clinical manifestations, 
including the drug-induced toxicity. It would therefore, be interesting to compare the paths 
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discovered for toxicity-inducing drugs with paths for drugs that are not known to cause drug-
induced neutropenia. Is it likely that some of the same proteins may be involved in both sets of 
paths ? What proteins, in paths discovered for drugs related to non-immune neutropenia, are 
also likely to be modulated in relation to other clinical effects and will therefore be ‘hotspots’ 
detected for a set of drugs not involved in non-immune neutropenia ?  What paths are common 
to both sets of drugs and how are they regulated under ‘toxic’ and ‘nontoxic’ conditions? 
In order to address the above questions, the algorithm was re-run on a set of drugs that are 
not known to cause drug-induced neutropenia. The choice of drugs used in this analysis was 
based on two criteria, namely manual curation by a toxicologist to confirm non-association 
with drug-induced non-immune neutropenia and availability of drug-specific gene expression 
data so as to enable implementation of the algorithm. Based on these criteria, a toxicologist 
collaborator performed manual curation to arrive at the list of drugs shown in Table 9.  
TABLE 9. Drugs not known to cause non-immune neutropenia 
Drug Therapeutic Category Description 
Acacetin Antineoplastic Agents 
Acacetin, a flalvinoid compound, has been studied for its 
anti-proliferative effects in human non-small cell lung 
cancer  
Bemegride 
CNS stimulants, 
AntiConvulsants, 
Respiratory system agents 
A CNS stimulant that is used to induce convulsions in 
experimental animals. It  has been used as a respiratory 
stimulant and in the treatment of barbiturate overdose. 
Benparidol Antipsychotic agent 
A butyrophenone with general properties similar to those 
of HALOPERIDOL. It has been used in the treatment of 
aberrant sexual behavior. (From Martindale, The Extra 
Pharmacopoeia, 30th ed, p567) 
Ethotoin AntiConvulsant Ethotoin is a hydantoin derivative and anticonvulsant.  
Ethionamide 
Leprostatic Agents  
Antitubercular Agents  
Fatty Acid Synthesis 
Inhibitors  
A second-line antitubercular agent that inhibits mycolic 
acid synthesis. It  also may be used for treatment of 
leprosy. (From Smith and Reynard, Textbook of 
Pharmacology, 1992, p868) 
Etomidate 
Hypnotics and Sedatives  
Anesthetics, Intravenous  
Imidazole derivative anesthetic and hypnotic with lit t le 
effect on blood gases, ventilation, or the cardiovascular 
system. It has been proposed as an induction anesthetic. 
Etodolac 
Hypnotics and Sedatives  
Anesthetics, Intravenous 
Etodolac is a non-steroidal anti-inflammatory drug 
(NSAID) with anti-inflammatory, analgesic and 
antipyretic properties. Its therapeutic effects are due to its 
ability to inhibit prostaglandin synthesis. It is indicated for 
of rheumatoid arthritis and osteoarthritis. 
Galantamine 
Parasympathomimetics  
Cholinesterase Inhibitors  
Nootropic Agents 
A benzazepine derived from norbelladine. Galantamine is 
a cholinesterase inhibitor that has been studied as a 
treatment for Alzheimer’s disease and other central 
nervous system disorders. 
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Table 9 (continued)   
Indapamide 
Antihypertensive Agents  
Diuretics 
A benzamide-sulfonamide-indole. It  is called a thiazide-
like diuretic but structure is different enough (lacking the 
thiazo-ring) so it  is not clear that the mechanism is 
comparable. 
Isosorbide 
Vasodilator Agents  
Nitrates and Nitrites  
Nitric Oxide Donors 
Isosorbide mononitrate is a drug used principally in the 
treatment of angina pectoris1 and acts by dilating the 
blood vessels so as to reduce the blood pressure. It  is sold 
by AstraZeneca under the trade name Imdur. 
Mestranol Estrogens 
The 3-methyl ether of ethinyl estradiol. It  must be 
demethylated to be biologically active. It  is used as the 
estrogen component of many combination ORAL 
contraceptives. 
Nalbuphine 
Narcotics  
Analgesics, Opioid  
Narcotic Antagonists 
A narcotic used as a pain medication. It  appears to be an 
agonist at kappa opioid receptors and an antagonist or 
partial agonist at mu opioid receptors. 
Nabumetone Antineoplastic Agents 
Nabumetone is a nonsteroidal anti-inflammatory drug 
(NSAID) of the arylalkanoic acid family (which includes 
diclofenac). Marketed under the brand name Relafen, it  
has been shown to have a slightly lower risk of 
gastrointestinal side effects than most other non-selective 
NSAIDs. 
Orlistat  
Enzyme Inhibitors  
Anti-Obesity Agents 
 Orlistat is a drug designed to treat obesity. Its primary 
function is preventing the absorption of fats from the 
human diet, thereby reducing caloric intake. Orlistat works 
by inhibiting pancreatic lipase, an enzyme that breaks 
down triglycerides in the intestine. Without this enzyme, 
triglycerides from the diet are prevented from being 
hydrolyzed into absorbable free fatty acids and are 
excreted undigested.  
Papaverine 
Vasodilator Agents  
Phosphodiesterase 
Inhibitors 
An alkaloid found in opium but not closely related to the 
other opium alkaloids in its structure or pharmacological 
actions. It is a direct-acting smooth muscle relaxant used 
in the treatment of impotence and as a vasodilator, 
especially for cerebral vasodilation. The mechanism of its 
pharmacological actions is not clear, but it  apparently can  
inhibit phosphodiesterases and it  may have direct actions 
on calcium channels. 
Pimozide Antipsychotic agent 
A diphenylbutylpiperidine that is effective as an 
antipsychotic agent and as an alternative to haloperidol for 
the suppression of vocal and motor tics in patients with 
Tourette syndrome. 
Raloxifane 
Antihypocalcemic Agents  
Osteoporosis Prophylactic   
Estrogen Antagonists  
A second generation selective estrogen receptor modulator 
(SERM) used to prevent osteoporosis in postmenopausal 
women. It  has estrogen agonist effects on bone and 
cholesterol metabolism but behaves as a complete 
estrogen antagonist on mammary gland and uterine tissue. 
Selegiline 
Central Nervous System 
Agents  
Antiparkinson Agents 
A selective, irreversible inhibitor of Type B monoamine 
oxidase. It  is used in newly diagnosed patients with 
Parkinson’s disease. It  may slow progression of the 
clinical disease and delay the requirement for levodopa 
therapy. It also may be given with levodopa upon onset of 
disability. (From AMA Drug Evaluations Annual, 1994, 
p385) The compound without isomeric designation is 
Deprenyl. 
 
Hereinafter, the set of drugs not known to cause non-immune neutropenia (listed in Table 9) 
will be termed as ‘control drugs’ and the set of drugs known to cause non-immune neutropenia 
(listed in Table 4) will be described as ‘toxicity-inducing’ drugs. All steps outlined in chapters 
3 and 4 were applied to this analysis and the methods will therefore not be repeated here. 
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Sections 5.1.2 summarizes results from a comparative analysis of DTSPs discovered for 
toxicity-inducing and control drugs.  
5.1.2  Results and Discussion 
Some characteristics of DTSPs for ’control’ drugs were found to be equivalent to their 
’toxicity-inducing’ counterparts. On average, 127 unique proteins were involved in 
statistically significant paths connecting drug targets for control drugs with toxicity-related 
proteins in the network. On average, 147 unique proteins were involved in statistically 
significant paths connecting drug targets for toxicity-inducing drugs with toxicity-related 
proteins in the network. This may imply that the density of interactions among the set of 
proteins involved on DTSPs for each group is more or less similar within the two groups. The 
average number of paths were also found to be similar (424 for toxicity-inducing drugs as 
opposed to 519 for control drugs) in both groups. As the algorithm is designed to identify 
paths maximising the product of gene expression score and the number of such paths desired 
is an input parameter to the algorithm, we find about the same number of paths in both groups. 
The algorithm ranks detected paths based on gene expression change relative to other paths 
for the same drug. If a path is found to be highly ranked for a drug, this may not necessarily 
imply that paths discovered for ’control’ drugs have the same extent of differential expression 
change (Treated vs. Control) compared to paths discovered for the ’toxicity-inducing’ drugs.  
Section 5.1.2.2 describes the difference in extent of gene expression change between the two 
groups. 
5.1.2.1 Toxicity-inducing vs Control drugs: Common path proteins and pathways 
 
If a protein is found to be involved in a statistically significant signaling path for a toxicity-
inducing drug, it may point to the protein’s topological relevance to the drug-induced toxicity, 
depending on the extent of gene expression change and functional association between the 
protein and patho-physiological processes involved in the drug-induced toxicity. However, if 
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the same protein is also found to be involved on paths for control drugs, this can be interpreted 
in many ways. First, it would be important to know the extent to which the path proteins are 
differentially expressed under each treatment condition. If a protein has topological relevance 
but unequal gene expression change under ‘control’ and ‘toxicity-inducing’ conditions, this 
may point to its role in drug-induced toxicity. On the contrary, if the protein is topologically 
relevant (i.e. involved on paths for both toxicity-inducing and control groups) but exhibits the 
same direction or lack of gene expression change irrespective of the drug treatment, this could 
make the protein less relevant to the drug-induced toxicity. If the protein is involved in paths 
for one set of drugs (either toxicity-inducing or control) but not the other, it could still be 
relevant to the toxicity depending on the extent and type (up-regulation or down-regulation) of 
gene expression change observed in each case. For example, if a path protein associated with 
increase in inflammation is found to be down-regulated after control drug administration, this 
may point to its role in inhibiting inflammatory cytokines thereby preventing any neutropenia 
related adverse effect after drug administration. This protein would be relevant to 
understanding toxic mechanisms even if it was not found to be involved in any statistically 
significant paths for the toxicity-inducing drugs. Interpretation of findings solely on the basis of 
protein involvement on paths within each group is therefore likely to be less accurate compared 
to a detailed analysis of the extent of gene expression change and the effect of this change on 
toxicity-related end nodes in the network. 
Key observations from identifying protein/s that are involved on at least one path for both 
groups and those that are only found on paths for one of the groups are as follows –  
- Out of the 424 unique proteins found to be involved in at least one path for the 
‘toxicity-inducing’ drugs, 272 proteins were also found to be involved in at least one 
path for the ‘control’ set of drugs. 152 proteins were only found on paths for the 
toxicity-inducing set while 247 proteins were found only on paths for the control drugs. 
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- Further analysis of the above set of proteins was carried out to understand whether 
specific canonical pathways were being modulated by each group of proteins. Geneset 
Enrichment for statistically significant KEGG pathway association was carried out 
using the WEBGESTALT application as described in section 3.1.5. The intention with 
geneset enrichment analysis was to understand whether some pathways were being 
modulated solely in the ‘toxicity-inducing’ set while other pathways were being 
modulated in both set of drugs. Figure 12 shows the top 10 pathways that were 
modulated by each set of proteins. 
 
Figure 11.  Venn Diagram shows the number of proteins common and exclusive to paths 
discovered for toxicity-inducing and control drugs. Geneset enrichment analysis revealed top 
10 canonical pathways associated with path proteins discovered for each set of drugs. Some 
known pathways (like MAPK, cancer pathways and GnRH signaling pathway) were found to 
be common across the groups. Some others (like drug metabolism – cytochrome P450, Focal 
adhesion) were exclusively associated with path proteins discovered for drugs that cause non-
immune neutropenia. 
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- Some known pathways like MAPK signaling and cancer-related pathways showed 
statistically significant association in both groups. This implies that distinct components 
of these pathways are involved in paths discovered for each group. This isn’t 
unexpected given observations that distinct set of proteins within the MAPK signaling 
cascade have opposing effects on apoptosis [Xia et al. 1995].  While it cannot be 
concluded solely on findings from this analysis, it is possible that some proteins 
associated with MAPK signaling activate processes that lead to drug-induced 
neutropenia while certain other proteins also associated with MAPK signaling exhibit 
the exact opposite effect under control treatment conditions. MAPK is a key signaling 
pathway known to modulate the therapeutic effects of chemotherapy drugs[Boldt et al. 
2002]. Detailed analysis of these path proteins with additional data and knowledge of 
up and down regulation of relevant proteins in the context of other changes may 
therefore, help understand the underlying toxicological processes better. 
5.1.2.2 Toxicity-inducing vs. Control drugs: Extent of genomic regulation 
 
As described in section 5.2, both topological relevance and extent of gene expression 
change in path proteins are important to understand when interpreting the results from this 
analysis. Topological relevance of proteins discovered for each set of drugs have been analyzed 
in section 5.2.  
In order to compare the extent of gene expression change in path proteins for the two set of 
drugs, an average of path expression scores for all paths was computed across all statistically 
significant paths for drugs in the toxicity-inducing and control set. Figure 13 shows a boxplot 
of the average score in each group. 
The boxplot implies that proteins involved in DTSPs for drugs in the ‘toxicity-inducing’ set 
exhibit greater extent of gene expression change (treated vs. control) compared to those for 
drugs in the ‘control’ set. In other words, the set of statistically significant paths discovered for 
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toxicity-inducing drugs may be ‘active’ under drug administration conditions while the set of 
paths discovered for control drugs are relatively ‘inactive’ from a gene expression standpoint.  
 
 
 
Figure 12.  Average Path expression score in each set reveals the greater extent of gene 
expression change (treated vs. control) in path proteins discovered for the Toxicity-inducing 
drugs. 
The advantage of using the DTSP algorithm on protein interaction networks and integrating 
gene expression data is clear from this observation. Topological relevance of a protein provides 
a rationale for studying its gene expression change and the extent of gene expression change 
indicates that one set of path proteins is more likely to yield a downstream effect in the form of 
a drug-induced toxicity. 
Some DTSPs were found to be common to both set of drugs. If a statistically significant 
path discovered for the toxicity-inducing drugs also exists in the control set, it would be 
important to know whether the extent and direction of gene expression regulation for such 
paths is different between the two set of drugs. If the end nodes on such paths are differentially 
regulated between the two sets of drugs, this may point to their role in drug-induced non-
immune Neutropenia. This is because Neutropenia is defined as a clinical significant reduction 
in Neutrophil count. Paths where the toxicity-related end node proteins are down-regulated, are 
Toxicity-inducing 
Drugs 
Control 
Drugs 
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therefore important because they may lead to reduction in Neutrophil production. The ‘toxicity-
inducing’ set of DTSPs were therefore, compared with all paths discovered for the control set 
to identify four common DTSPs. The extent of gene expression regulation in the end nodes 
(known hematopoiesis-related proteins) was calculated (ratio of treated and control) for each 
common path. Table 10 shows the four paths and the gene expression ratio for the end nodes 
for each path. 
Colony stimulating factor CSF3,  an end node for paths (depicted as a chain of HGNC 
symbols) IL1B-MAPK14-STAT1-CSF3 and REN-EDN1-ACE1-CSF3 was marginally down-
regulated (treated/control) for the first path in both toxicity-inducing as well as control group 
while in the second path, CSF3 was found to be marginally up-regulated in both, the toxicity-
inducing and the control set. The longer path that started at CCND1 also led to marginal up-
regulation of its end node CSF2 in both sets of drugs. DTSPs common to both groups and 
regulation of toxicity-related proteins on those paths. 
TABLE 10. DTSPs common to both groups and regulation of toxicity-related 
proteins on those paths 
 
KITLG (KIT Ligand) was the only end node that was found to be marginally down-
regulated in the toxicity-inducing set and marginally up-regulated in the control set. This 
implies that down-regulation of KITLG via EGFR and SHC1 proteins may lead to reduced 
Drug-Toxicity Signaling Path (DTSP) 
Toxicity-
inducing 
Drugs 
Ratio 
(Trt/Ctl) 
Control 
Drugs 
Ratio 
(Trt/Ctl) 
IL1B MAPK14 STAT1 CSF3       0.939631803 0.944454842 
REN EDN1 ACE1 CSF3       1.016675682 1.112032776 
CHRM1 EGFR1 SHC1 KITLG       0.857261358 1.095764547 
CCND1 STAT3 SRC5 GJA1 MAPK3 FOS1 CSF2 1.078424425 1.015210632 
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Neutrophil production due to toxicity-inducing drugs. This observation needs further 
experimental confirmation to evaluate the range of expression change in KITLG and 
corresponding change in Neutrophil production. 
The role of KITLG as a key network protein involved in drug-induced non-immune 
neutropenia as hypothesized in Section 4.3.4 and its inclusion as a potential biomarker is 
therefore, supported with this comparative analysis of paths discovered for the toxicity-
inducing and control drugs. 
5.2 Comparative Evaluation of algorithm accuracy 
The integration of gene expression and protein interaction information may seem to offer a 
more comprehensive model compared to using either ‘omics’ platform by itself. However, a 
statistical evaluation of the DTSP algorithm is necessary in order to understand its predictive 
ability compared to the most prevalent toxicogenomics method. To achieve this, microarray 
data analysis was performed using the same gene expression dataset that was used earlier to 
compute the gene expression measure. Results from all algorithms were compared against 
results from microarray data analysis. The choice of microarray data analysis for comparison 
was driven by two factors:  
1. As the first high-throughput ‘omics’ platform that developed and evolved after the 
human genome project, gene expression-based measurements are relatively mature 
compared to protein expression and metabonomics platforms. Affymetrix Genechip 
arrays have been known to deliver repeatable results when performed under quality-
controlled experimental conditions. The other ‘omics’ platforms (proteomics and 
metabonomics) are relatively newer and drug-specific data for these platforms are not 
widely available.  
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2. Microarray gene expression data are publicly available and extensively used for 
toxicogenomics applications [Roth et al. 2011, Mongan and Hamadeh 2011, Afshari 
et al. 2011, Hamadeh et al. 2002]. 
The following section describes steps implemented to analyze microarray gene expression 
data. 
5.2.1 Microarray Data Analysis 
Analysis of raw data collected using a microarray platform involved the following steps: 
1. Raw CEL files for one or more treated samples and more than one control sample for 
each treated sample were downloaded for each ‘toxicity-inducing’ drug from the 
connectivity map server. CEL files (treated and 1-4 vehicles scans) for 51 experiments 
were downloaded for the 19 toxicity-inducing drugs analyzed in this study. For the 18 
control drugs, CEL files (treated and 1-4 vehicles) for 41 experiments were 
downloaded. There were one or more treated samples for each drug (dose: 10µM, 
duration: 6 hours) and multiple vehicle scans from HT_HgU133 chip array in NCI 
MCF7 cell lines. 
2. The ‘ExpressionFileCreator’ module in GenePattern was used to convert CEL files into 
gct format expression files [Reich et al. 2006]. Robust multichip average (RMA) 
measure was used for conversion and quantile normalization was applied. 
3. The average log ratio of treated/average(vehicle) values were calculated for each 
probeset and gene expression data for all drugs were combined into a single gct file 
with class labels ‘toxicity-inducing’ and ‘control’. 
4. The gene expression dataset was then analyzed using the 
‘ComparativeMarkerSelection’ module in GenePattern. The 22277 probesets on 
HT_HgU133 chip were ranked using the ‘Signal to Noise’ (SNR) test statistic – 
SNR = (µtoxic - µcontrol)/(σtoxic + σcontrol) 
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where   µtoxic – Mean value for a probeset in the ‘toxicity-inducing’ set 
 µcontrol - Mean value for a probeset in the ‘control’ set 
 σtoxic – Standard deviation for a probeset in the ‘toxicity-inducing’ set 
 σcontrol – Standard deviation for a probeset in the ‘control’ set 
Use of the SNR test statistic ensured that probesets with largest difference in mean 
expression value between the two sets and least standard deviation within the two sets were 
ranked higher. 
 
5.2.2  Choice of Benchmark Database 
In order to compare outputs from the two DTSP algorithms with results from microarray 
data analysis, benchmark data associating specific network proteins with the drug-induced 
toxicity were required. The Comparative Toxicogenomics Database (CTD), with its collection 
of chemical–gene, chemical–disease and gene–disease relationships manually curated and 
inferred from published literature was used for this purpose. The database is dedicated to 
promoting the exploration and development of testable hypotheses about the effects of the 
environment on human health [Davis et al. 2011]. 
A significant number of relationships in the CTD result from computation of an inference 
score. The inference score reflects the degree of similarity between CTD chemical–gene–
disease networks and a similar scale-free random network. Many biological networks, such as 
disease and metabolic networks, have been shown to be scale-free random networks. The score 
takes into account the connectivity of the chemical, disease and each of the genes used to make 
the chemical disease inference. The higher the score, the more likely the inference network has 
non-uniform connectivity as observed in scale-free random networks. 
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Figure 13.  CTD integrates curated data for chemical-gene interactions, chemical- disease and 
gene-disease relationships (colored circles) with select public datasets (gray circles; pathways 
from the KEGG and Reactome databases and GO annotations). Solid lines describe directly 
curated or integrated relationships and dashed lines describe inferred relationships. (Figure 
and Legend reproduced from the BioInformatics Primer, Pathway Interaction Database, 
Mattingly 2011)[Mattingly et al. 2006] [Davis et al. 2011] 
As summarized in Table 11, CTD provides ~325,000 curated chemical-gene interactions 
and ~1,500,000 curated and inferred Gene-Disease relationships. A major strength of CTD is 
that these core data are manually curated from the literature by professional biocurators [Salimi 
and Vita 2006], ensuring accuracy. CTD does use text mining to triage the literature, but each 
reference (abstract or full-text) is read by biocurator to identify interactions and relationships, 
and all curated data is supported by its source citation. The manual curation approach at CTD 
allows biocurators to validate every interaction and relationship, ensure that the correct 
chemical name and gene symbol is used, and generate detailed descriptions of the types of 
interaction. Data are uploaded to the database monthly. The CTD was therefore used as a 
benchmark to compare results from microarray analysis with results from the two DTSP 
algorithms proposed in this thesis.  
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TABLE 11. CTD data status as of May 2011 (summarized from BioInformatics 
Primer, Mattingly 2011) 
Description Data Count 
Chemical-Gene curated Interactions 325,342 
Gene-disease relationships 1,575,076 
- Curated 13,187 
- Inferred 1,561,889 
Chemical-disease relationships 334,448 
- Curated 11,378 
- Inferred 323,070 
 
5.3 Results and Discussion 
Hereinafter, the DTSP Algorithm described in chapter 3 will be referred to as the 
’DTSP_Edgecent’ (for Edge Centrality measure) algorithm and the DTSP algorithm described 
in chapter 4 (combining protein interaction network and gene expression measure) will be 
referred to as ‘DTSP_GeneExp’ algorithm. The two algorithms were compared with results 
from microarray data analysis described in section 5.2.1. Comparison of results was carried out 
as follows: 
1. Results from each algorithm (path proteins in case of the two DTSP algorithms and 
probesets in case of microarray data analysis) were mapped to genes in order to enable 
comparison with neutropenia-related genes provided by the Comparative 
Toxicogenomics database. 
2. Genes common to the three sets, i.e. the human subset of the STITCH database, the 
HT_HgU133 chip genes and CTD database genes were identified. This was the larger 
set of common genes from which each algorithm mined a smaller set of ‘toxicity-
related’ genes. 
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3. From within this common set, the DTSP_Edgecent algorithm identified 182 unique 
genes involved on paths discovered for the toxicity-inducing drugs. The 
DTSP_GeneExp algorithm identified 417 unique genes involved on paths discovered 
for the toxicity-inducing drugs. The top 500 genes (ranked by SNR statistic described 
in section 5.2.1) from microarray data analysis were compared with results from the 
two DTSP algorithms using the CTD benchmark. 
Comparison of the two DTSP algorithms with results from microarray data analysis was 
undertaken using gene-neutropenia-drug relationships from the CTD database as a reference. 
The CTD database contained less than 25 manually curated relationships between 18 genes and 
neutropenia-related disorders (including severe congenital 1/2 autosomal dominant, 
Poikiloderma with Neutropenia disorder and chronic idiopathic subtypes) and not all gene-
neutropenia relationships were found in the context of drug administration. The number of 
inferred relationships in the database was much higher, each with an inference score that 
ranged from about 1.9 (indicating weak association) to 140 (indicating strong association).  
In order to explore changes in accuracy estimates with use of different inference score 
thresholds for identifying a ‘positive set’ inside the CTD benchmark, three different ‘positive’ 
set of genes were considered – 
Set 1:  All Neutropenia genes with direct (manually curated) evidence in CTD 
Set 2:  List of top 500 neutropenia genes in CTD (direct and inferred evidence) 
Set 3:  All Neutropenia genes with direct and inferred evidence for association with the set 
of toxicity-inducing drugs used for the DTSP algorithm. 
Results from comparative evaluation of each algorithm using Set 1 is summarized below: 
Out of the 18 unique genes that were associated with various subtypes of neutropenia, 11 
were associated with the higher-granularity disease ‘neutropenia’, 5 with congenital subtype or 
cyclic subtype of the disease, one with ‘granule deficiency’ and one with ‘Poikiloderma with 
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Neutropenia’. Out of the 11 genes associated with ‘Neutropenia’, 4 were associated with 
genetic polymorphisms in some cases associated with genes that degrade specific  
chemotherapy drugs. Given that in vitro gene expression data used in this analysis was 
primarily aimed at detecting gene expression changes from drug administration using in vitro 
tissue samples and evidence for genetic polymorphism may not imply a functional effect under 
drug administration conditions, it was considered appropriate to compare algorithm results with 
the remaining set of genes. Out of the 7 remaining genes in the ‘positive’ set, 5 genes (71%) 
were detected using the DTSP-GeneExp algorithm, 2 genes (29%) were detected using the 
DTSP-Edgecent algorithm and 1 gene (14%) was ranked among the top 500 with microarray 
data analysis. 
For the ‘positive’ sets 2 and 3 in CTD, the following measures were computed 
a. True Positives (TP): Number of genes identified as toxicity-related using an 
algorithm that are also associated with the toxicity inside CTD. 
b. False Positives (FP): Number of genes identified as toxicity-related using an 
algorithm that are not associated with the toxicity inside CTD. 
c. True Negatives (TN): Number of genes identified as NOT toxicity-related using 
an algorithm that are NOT associated with the toxicity inside CTD. 
d. False Negatives (FN): Number of genes identified as NOT toxicity-related using 
an algorithm that are associated with the toxicity inside CTD. 
e. Sensitivity = TP/(TP + FN) 
f. Specificity = TN/(FP + TN) 
g. Positive Predictive  Value = TP/(TP + FP) 
h. Negative Predictive Value = TN/(TN + FN) 
i.  False Discovery Rate = FP/(FP + TP) 
j.  Accuracy = (TP + TN)/(TP + TN + FP + FN)  
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For set 2, the top 500 genes (ranked by inference score) were considered as the CTD 
‘positive’ set and for set 3, all 4004 genes (with direct and inferred evidence) were considered 
as the CTD ‘positive’ set. Table 12 shows measures computed for both sets.  
TABLE 12.Comparative Evaluation of DTSP algorithms 
 
CTD (Top 500) 
CTD - all ‘neutropenia’ genes  
(4004) 
Measure 
Microarray  
(top 500) 
DTSP 
EdgeCe
nt 
DTSP 
GeneExp 
Microarray  
(top 500) 
DTSP 
EdgeCent 
DTSP 
GeneExp 
True 
Positives 
37 
(7.4%) 
80 
(44%) 
141 
(34%) 
231 
(46%) 
136 
(74%) 
296 
(71%) 
False 
Positives 
463 
(93%) 
102 
(56%) 
276 
(55%) 
269 
(54%) 
46 
(25%) 
121 
(29%) 
True 
Negatives 
10274 
(96%) 
10635 
(96%) 
10461 
(97%) 
6964 
(65%) 
7187 
(65%) 
7112 
(66%) 
False 
Negatives 
463 
(4.3%) 
420 
(3.7%) 
359 
(3.3%) 
3773 
(35%) 
3868 
(35%) 
3708 
(34%) 
Sensitivity  0.074 0.16 0.282 0.032 0.034 0.074 
Specificity  0.96 0.99 0.97 0.93 0.99 0.98 
PPV  0.074 0.44 0.34 0.46 0.75 0.71 
NPV  0.96 0.96 0.97 0.35 0.65 0.66 
FDR 0.93 0.56 0.66 0.538 0.25 0.29 
Accuracy 0.92 0.95 0.94 0.36 0.65 0.66 
 
Both DTSP algorithms showed a significant improvement over standard microarray data 
analysis for the two sets. A five-fold improvement in ‘true positives’, two-fold improvement in 
‘false positives’ and marginal improvements in ‘true negatives’ was observed with the DTSP 
algorithms with set 2 (CTD Top500),. However, due to high proportion of ‘False positives’ 
(partly attributable to a stringent cut-off for number of genes in the ‘true positive’ set), the 
sensitivity with all three methods was impacted. The two DTSP algorithms showed distinct 
improvement in sensitivity over microarray data analysis, with the DTSP-GeneExpression 
approach showing the highest sensitivity among the three methods. Specificity was high with 
all three methods, implying that if a gene was found to be associated with the drug-induced 
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toxicity using either methods, there was 3-4% chance that this would be a ‘false positive’ 
finding, with the DTSP algorithms having marginally improved specificity. 
In terms of overall accuracy, the DTSP_Edgecent algorithm marginally outperformed the other 
two methods, with 95% accuracy followed by DTSP_GeneExp algorithm (94% accuracy) and 
Microarray data analysis with 92% accuracy. 
Set 3 used a bigger ‘positive’ set, which improved the proportion of ‘true positives’ detected 
with all three methods at the expense of higher ‘false Negatives’. As a much higher number of 
‘true positive’ genes was identified inside the CTD benchmark (total 4004 genes) compared to 
the number of genes identified as toxicity-related from microarray data analysis (top 500, 
ranked by Signal-to-Noise ratio statistic), there were a higher proportion of false negatives with 
set 3.   
However even with set 3, the two DTSP algorithms outperformed microarray data analysis 
in terms of ‘true positives’ detected (46% for microarray data analysis, 74% for 
DTSP_Edgecent and 71% for DTSP_GeneExp), Specificity (93% for microarray data analysis, 
98% for DTSP_GeneExp and 99% for DTSP_Edgecent), Positive Predictive Value (46% - 
Microarray, 71% - DTSP_GeneExp and 74% - DTSP_Edgecent) and Overall accuracy (36% - 
Microarray, 65% - DTSP_Edgecent and 66% - DTSP_GeneExp). 
The advantages of using the DTSP approach over standard microarray analysis are apparent 
from the above analysis. However, there is only a marginal difference in measures for the two 
DTSP algorithms and on some measures (e.g. %True positives, PPV and Specificity) the edge 
centrality-based DTSP algorithm marginally outperformed the gene expression-based 
approach. Does this necessarily imply that the edge centrality-based approach is superior to the 
gene expression-based approach? Further analysis is recommended before one DTSP approach 
can be preferred over the other. The following aspects of the comparative evaluation and the 
two DTSP algorithms need further consideration -  
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1. The gene expression measure emphasizes network dynamics (temporal changes in gene 
expression after drug administration) when identifying toxicity-related proteins whereas the 
edge centrality approach emphasizes topological connectivity. Understanding and 
incorporating network dynamics into a large network model may be inherently more 
complicated than computing edge centrality with the assumption that connectivity determines 
‘interestingness’ irrespective of temporal changes that may happen to the network after drug 
administration. Given the limited amount of available evidence from comparative evaluation 
that demonstrates marginal superiority for the edge centrality approach, the choice of one 
DTSP algorithm over the other remains unclear. Further investigation is required, both in terms 
of using additional gene expression data as well as integrating additional data types, in order to 
refine the gene expression based approach. Edge centrality seems to provide an interesting 
alternative view on drug-toxicity signaling path but whether choice of a biomarker panel can be 
based solely on network connectivity remains to be seen. A measure that combines the 
strengths of the two DTSP algorithms may perhaps lead to an improved specificity and 
sensitivity over using the two distinct measures. 
2.  The choice and availability of an appropriate benchmark for evaluating such algorithms 
needs further investigation. CTD provides a high-quality resource that catalogs relationships 
between genes, diseases and chemicals from a variety of sources. However, for algorithms like 
the ones developed in this thesis and those that are implemented on large integrated networks, 
some of the same underlying sources would be used (e.g. co-occurrence between genes and 
diseases inside published literature) to populate both the STITCH/STRING databases and the 
CTD/benchmark. There is a need to identify benchmark databases that capture gene-chemical-
disease relationship from independent experimental/direct evidence sources. Also, CTD 
provides many types of gene-disease-drug relationships, only of some of which can be 
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expected to be detected using the DTSP approach, at least partly due to the algorithm 
limitations with using only two data types. 
 
Figure 14.  The CTD curation and integration paradigm (reproduced from Davis et al. 
2011[Davis et al. 2009]. Evidence for a direct gene-chemical relationship and a direct 
chemical-disease relationship forms the basis for an inferred gene-disease relationship. 
Moreover, as shown in Figure 15, inferred relationships between genes and disease in the 
CTD are based on the paradigm that if there is direct evidence in published literature 
associating a gene with a particular chemical and if there is also direct evidence that the same 
chemical is associated with a toxicity, then it is inferred that the gene and the disease may also 
be related. This paradigm contradicts underlying assumptions made with the two DTSP 
algorithms that primary or secondary drug targets (proteins) are only relevant if they enable 
topologically connectivity with proteins known to be associated with the drug-induced toxicity 
(i.e. DTSP_Edgecent algorithm) and are involved in highly differentially regulated drug-
toxicity signaling paths (ie. DTSP_GeneExp algorithm). The ‘positive’ set identified with the 
benchmark, therefore requires further refinement in order to distil the specific genes that can be 
definitively linked to drug-induced non-immune neutropenia and not neutropenia in general 
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(includes congenital and many other subtypes of the disease). The apparent lack of sensitivity 
with all three methods can be at least partly attributed to the above limitations with using a 
comparison benchmark. 
On the other hand, interpretation of results from signaling path detection approaches like the 
DTSP algorithms requires further refinement in path protein subsets. Further analysis of 
discovered paths may lead to identification of protein subsets that are unique to the drug and its 
mechanism of action and therefore, have a stronger association with the drug than to drug-
induced toxicity across a set of drugs. 
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CHAPTER 6: CONCLUSIONS AND FUTURE WORK 
 
The ability to apply signaling path detection to in silico toxicity evaluation offers 
exciting opportunities. This thesis demonstrates how background knowledge about drugs and 
their effects can be utilized in conjunction with a network-based model to discover toxicity-
related path proteins. Integration of protein interaction and gene expression information yields 
insights into the dynamic changes that occur at a systems level after drug administration. 
Drug-Toxicity signaling paths and discovery of common characteristics of path proteins 
across a set of drugs provides opportunities for understanding toxic mechanisms and possible 
biomarker panels that can, in the future be used for screening new drug candidates.  The 
DTSP algorithm represents one of the first steps towards driving an area of research in 
systems toxicology that can lead to increasingly accurate and comprehensive in silico toxicity 
evaluation models.  
6.1 Thesis Contributions 
This thesis has made the following important contributions: 
First, the drug-toxicity signaling path detection algorithm is a unique approach for 
discovering signaling paths inside protein interaction networks that are directly relevant and 
downstream from drug target proteins and upstream from toxicity-related proteins inside a 
large protein interaction network. The DTSP algorithm is the first to apply signaling path 
detection to in silico toxicity evaluation. 
Second, both local and global properties of biological networks have recently been studied 
and applied towards prediction of protein function. However, the definition and 
implementation of an edge centrality measure for detection of drug-induced toxicity hotspots 
inside protein interaction networks is a unique contribution of this thesis.  
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Third, algorithms aimed at re-engineering biomolecular networks from gene expression data 
and integration of genomic-proteomic data have been proposed recently. However, integration 
of gene expression and protein interaction data for detection of toxicity hotspots is a unique 
contribution of this thesis. 
Four, yet another unique contribution of this thesis is a biomarker panel associated with 
drug-induced non-immune neutropenia, discovered using the DTSP algorithm. 
The following section summarizes the next steps and areas in which the DTSP algorithm 
can be extended in the future. 
6.2  Recommendations for Future Work 
6.2.1  Experimental Confirmation 
Validation of the DTSP algorithm is a necessary pre-requisite for the approach to be 
considered as a toxicity screen in pharmaceutical R&D. In order to confirm that the biomarker 
panel proposed in chapter 3 is predictive of drug-induced non-immune neutropenia, the results 
will need to be replicated on other drugs that are known to cause the toxicity. Laboratory-based 
experiments on identified path proteins may provide experimental evidence to support the 
preliminary hypothesis.  
6.2.2   Applicability to other drug-induced toxicities 
If the algorithm can be implemented and evaluated for toxicities with high-quality 
benchmark data that supports drug-toxicity association and protein-toxicity relationships, this 
will provide greater confidence in its ability to detect toxicity-specific protein hotspots inside 
large biological networks. Discovery of toxicity hotspots using the DTSP algorithm requires 
availability of in vitro gene expression data. In addition to this, some of the additional data 
types outlined in section 6.2.3 may also improve screening of candidate paths to reveal those 
that are directly related to the toxicity of interest. 
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6.2.3  Incorporation of Additional data types  
Systems analysis for detection of toxicity hotspots can potentially utilize many other data 
types. The metric used for weighting edge of the network of reliable paths in the DTSP 
algorithm, can incorporate additional background knowledge on network proteins, such as 
miRNA (microRNA) annotations and protein localization information. For example, when 
considering events like hepatotoxicity, paths consisting of proteins known to be localized in 
the liver may be considered more relevant. Incorporation of miRNA annotations for path 
proteins may reveal common regulators of proteins involved in drug-toxicity signaling paths. 
Improved mechanistic understanding of pathway regulation may lead to improved biomarkers 
for prediction of drug-induced toxicities. The algorithm may also benefit from additional data 
types in the form of chemical properties of the drugs, pharmacokinetic properties and 
pharmacodynamic changes at various time points after drug administration as well as higher 
level canonical pathway annotations of network nodes. Finally, drug-toxicity signaling paths 
that are ‘active’ only in the presence of more than one drug, may be associated with adverse 
effects that result from administration of multiple drugs [Tatonetti et al. 2012]. Understanding 
drug-drug interactions through the lens of automatic signaling path detection may be an 
important benefit from our approach. 
6.2.4  System-wide temporal and stochastic simulation 
Protein interaction network analysis described in this thesis represents a non-temporal, 
non-dynamic, semi-stochastic , ‘top down’ approach starting at drugs and their clinical effects, 
using a constructed protein interaction network and analyzing it to understand the role of 
proteins involved on drug-toxicity signaling paths. An alternative approach would be to utilize 
a ‘bottom up’ approach, where individual components of the network are first studied in 
greater detail. The bottom up approach starts with identifying regulation functions for each 
network element and gradually building the holistic picture of the system, at the protein, 
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pathways, tissue, organ and organism leve1. However, analysis of smaller metabolic networks 
has been undertaken by many other researchers to leverage the ‘bottom up’ approach. One of 
the limitations with adopting a thorough quantitative approach at the level of a large network 
is the scarcity of temporal data on protein interactions and all levels above it (pathways, cell, 
tissue and organ) for the human biological system. This limitation is rapidly being replaced by 
the limitation in our ability to mine these networks to reveal the ‘truth’ underlying patho-
physiological phenomena.  
6.2.5 Network Medicine 
Drugs of the future may be able to target sub-networks instead of proteins, thereby giving 
rise to a completely new approach to drug discovery, recently termed as ‘network medicine’. 
Pawson et al. suggest two different strategies to drive network medicine, one involves a 
synthetic biology approach that aims at rewiring (adding new interactions) of the network using 
small molecules or novel synthetic modular proteins. This strategy exploits the modular nature 
of signaling proteins to change the topology and wiring of the network by adding or deleting 
interactions. The second approach relies on changing the information flow inside the network 
by targeting the phosphorylation states of key proteins. 
As systems biology is a relatively nascent field, many more approaches for targeting protein 
hotspots or modules directly may emerge over the next decade. Our ability to understand the 
dynamics of biological networks would be the key to discovering safe and efficacious 
therapeutic interventions. 
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Appendix A:  Graph Theoretic Definitions 
 This thesis adopts the graph-theoretic definitions proposed by Diestel [Diestel 2005]. A 
graph is a pair G = (V, E) of sets such that E Є [V2] and V Ω E = ф . The elements of V are 
vertices (or nodes) of the graph G, the elements of E are its edges (or lines).  The usual way to 
picture a graph is by drawing a dot for each vertex and joining two of these dots by a line if 
the corresponding two vertices form an edge. 
 The degree (or valency) dG(ν) =  d(ν) of a vertex ν is the number |E(ν)| of edges at ν ; by 
our definition of graph, this is equal to the number of neighbors of ν. A vertex of degree 0 is 
isolated.  
 A path is a non-empty graph P = (V,E) of the form 
 V = { x0, x1 , x2 , ……… xk }                              E = { x0x1, x1x2, x2x3 ………. Xk-1Xk}  
 where the xi are all distinct. The vertices x0 and xk are linked by P and are called its ends; 
the vertices x1 , x2 , ……… xk-1 are the inner vertices of P. The number of edges of a path is its 
length, and the path of length k is denoted as P
k
. k is allowed to be zero. A path is often 
referred to by the natural sequence of its vertices, say P =  x0x1 x2  ……… xk and calling P a 
path from x0 to xk .  
 A subgraph of a graph G is a graph whose vertex and edge sets are subsets of those of 
G. A supergraph of a graph G is a graph that contains G as a subgraph.  The graph is 
directed if its edges are directed (pointing toward either one of the ends) and undirected 
otherwise. A graph is complete (or called a clique) if every node has a connecting edge to 
every other node.  
 The complete graph on n vertices is often denoted by Kn where Kn would have n(n-1)/2 
vertices. 
 The clustering coefficient is used to quantify the extent to which a node is a 
cluster member. For example, in a network, if a node is directly connected to five 
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neighbors, the clustering coefficient calculates the ratio of the number of direct links 
observed among the five neighbors over the number of possible direct links among the 
five neighbors. If all five neighbors are fully interconnected, the node is said to have a 
high clustering coefficient (value of 1) and vice versa (value of zero). Formally, the 
clustering coefficient is defined as 
Ci = 2n /k i(ki-1)’ 
where n denotes the number of direct links connecting the ki nearest neighbors of node 
i. The clustering coefficient is 1 for a node at the center of a fully inter-linked cluster, 
while it is zero for a node that is part of a loosely connected group. A global 
measurement related to Ci is the average clustering coefficient C over all nodes in the 
network, characterizing the overall tendency of nodes to form clusters or groups. 
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